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In this study, antibody phage display technology was used to generate a broad panel of fully 
human monoclonal antibodies that target TcdB, one of the main virulence factors of 
Clostridioides difficile and target of new therapeutic approaches.   
TcdB has a complex domain structure and intoxicates cells via a multistep mechanism, thus 
offering several weak points which can be addressed with antibodies. 
Applying different panning strategies against either full TcdB, truncated variants or single 
domains, 36 unique scFvs were generated of which 31 were further characterized after 
conversion into the bivalent scFv-Fc format. ELISA and Immunoblot analysis proved TcdB 
binding and domain specificity of these 31 antibodies analyzed, and confirmed the selection 
of antibodies with diverse binding characteristics.  
Using a cell-based in vitro assay, all antibodies were screened for neutralization of TcdB 
induced cell rounding. Here two antibodies efficiently neutralized TcdB.  
To test whether in vitro neutralization could be further improved by targeting different 
domains of TcdB at the same time, antibody combinations were tested in in vitro neutralization 
of TcdB induced cell rounding. Unfortunately, for the combinations tested in this study, the 
improvement of neutralization observed was rather of additive than synergistic nature.  
To gain more information about the binding sites of the antibodies two independent 
approaches of epitope mapping were followed. With the combination of Peptide array and 
TcdB-fragment phage display, novel and already described epitopes on TcdB could be 
identified. By correlating these epitopes with the in vitro neutralization efficacy, a new epitope 
within the glucosyltransferase domain of TcdB was identified which conveys neutralization.  
Thus, this study provides valuable information for further development of therapeutics against 
TcdB. Also, the two potent neutralizing antibodies might be candidates for further preclinical 
development. Future therapeutic use of these antibodies, preferably as antibody combination 
with antibodies targeting different domains or epitopes, is easily conceivable due to the human 
origin of these antibodies. 
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Antibodies, also called immunoglobulins (Ig), are key molecules of the humoral adaptive 
immune response of gnathostomata. In a highly specific manner, they bind structures which 
are recognized as foreign or potentially dangerous e.g. viruses, bacteria, and parasites as well 
as molecules which are secreted by these pathogens. To render their target structures harmless, 
antibodies use three different mechanisms. Firstly, binding of the antibody can result in 
neutralization (of toxins, bacteria etc.) e.g. by inhibition of receptor binding. Secondly, 
opsonization triggers ingestion and elimination of pathogens by phagocytes and thirdly 
activation of the complement system starts a proteolytic cascade which leads to the destruction 
of the pathogen by the membrane attack complex (Murphy and Weaver, 2018).  
With these diverse assignments, antibodies act as a link between humoral and cellular as well 
as adaptive and native immune response. The complex function of an antibody is also reflected 
in its structural features: to specifically bind to very heterogeneous antigens, antibodies need 
a region with high variability, but to interact with other components of the immune system a 
constant part is also required (Murphy and Weaver, 2018). 
 
1.1.1 Antibody structure and recombinant antibody formats 
Antibodies consist of four polypeptide chains, two identical heavy chains (50 kDa for IgG) 
and two identical light chains (25 kDa). Depending on the chromosomal origin of the light 
chain they can be divided in lambda (λ) and kappa (κ) light chains. In humans the ratio between 
λ-and κ antibodies is 2:1 (Murphy and Weaver, 2018). 
The heavy chains are coupled to each other via disulfide bounds and each heavy chain is 
additionally linked to one light chain, again by a disulfide bond, which leads to a Y-shaped 
structure of the molecule (Murphy and Weaver, 2018). 
Referring to the structure and the originating gene locus of the heavy chain, human antibodies 
can be classified into IgM-, IgD-, IgG-, IgE- and IgA isotypes. These structural differences 
facilitate specialized functions for all five antibody classes, e.g. in primary immune response 
(IgM) or in the defense of antigens on mucous membranes (IgA) (Woof and Kerr, 2006; Woof 
and Russell, 2011) . The most abundant antibody in human sera is the IgG antibody (Natvig 
and Kunkel, 1973).  
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The heavy and light chain of the IgG are composed of several ß-barrel immunoglobulin 
domains, designated as VH, CH1, CH2, CH3 and VL and CL, respectively, where V stands for 
variable and C for constant or crystallizable (Edelman et al., 1969).  
 
The V domains of both, heavy and light chain, harbor 3 highly variable loops, so-called 
complementary determining regions, which are stabilized by the more conserved framework 
regions. These loops are involved in antigen binding and define the antibody’s specificity. 
Together with neighboring amino acids of the frameworks, they form the paratope, the 
interaction face between antibody and antigen (Murphy and Weaver, 2018; Sela-Culang et al., 
2013). The variable antibody portion, built up by VH and VL, is also designated as fragment 
variable. Adding CH1 and CL generates a so called Fragment antigen binding (Fab) (Edelman 
et al., 1969; Gitlin and Merler, 1961; Porter, 1959). In case of IgG, IgA and IgD, the Fab is 
coupled to CH2 and CH3 via a hinge region, which is a flexible linker connecting CH1 and CH2. 
For IgG, IgA and IgD the hinge also harbors Cysteines which are necessary for dimerization 
of the molecule. CH2 and CH3 (in case of IgM and IgE also CH4) form the Fragment 
crystallizable or Fragment constant (Fc), the constant part of the antibody. The antibody’s Fc 
part fulfills various mediator functions of the immune response, like binding to and thereby 
activating of the complement system (via C1q), thus triggering native immune response 
(complement dependent cytotoxicity, CDC) as well as binding to Fc specific cell surface 
A B 
Figure 1-1: Structure of an IgG molecule 
A) Schematic representation of an IgG and its domains. The heavy chain (red and grey) is composed of four domains (VH, 
CH1, CH2, CH3), the light chain (turquoise) consists of two domains (VL and CL). The polypeptide chains are connected 
covalently via disulfide bonds. VH and VL together build the Fragment variable (Fv), the Fragment crystallizable (Fc, grey) 
consists of CH2 and CH3.  
B) 3D structure of a crystallized IgG (Protein Data Bank 1IGY) visualized in cartoon style with transparent surface. The 
colors match to the schematic representation. 
 
Dissertation Viola Fühner  Introduction 
3 
 
receptors like FcγRI, FcγRIIa, FcγRIII, FcαRI and FcεRI which modulates the cellular 
immune response (Kapur et al., 2014; Mkaddem et al., 2014; Sutton and Davies, 2015) 
Structural and sequential differences between antibody classes and subclasses within the CH2 
and CH3 domains result in variations in the mediation of the immune response, mainly due to 
differences in affinity to the respective Fc receptors on the different cell types (Sun, 2014). 
Since the late 1980th, with the establishment of recombinant DNA methods, ca. 100 different 
antibodies formats have been designed meeting the various requirements for its diverse appli-
cations (Brinkmann and Kontermann, 2017; Carter, 2006; Spiess et al., 2015)  
For use in research, diagnostics and therapy, when no effector function is required, VH and VL 
can be covalently coupled via a short (often 15 AA) peptide linker to obtain a single chain 
fragment variable (scFv) (Figure 1-2). With a molecular weight of only 25-30 kDa this 
recombinant antibody fragment still completely replicates both, affinity and specificity of its 
parent antibody (Bird et al., 1988; Huston et al., 1988). Due to its small size it can penetrate 
tissue more easily than larger antibody fragments, but it is also less stable and has a reduced 
serum half-life (Röthlisberger et al., 2005; Thiel et al., 2002; Unverdorben et al., 2015). 
 
In an scFv-Fc, the scFv is coupled to the IgG CH2 and CH3 domains via the hinge region. Due 
to dimerization mediated by the hinge region and because of the Fc domain, which conciliates 
effector functions, the scFv-Fc has IgG like properties (Powers et al., 2001) (Figure 1-2). 
Furthermore, this format is easily producible in mammalian cell culture, which makes it an 
attractive format for initial antibody development (Frenzel et al., 2013).   
Figure 1-2: Recombinant antibody formats used in this study 
In the scFv VH and VL are coupled via a peptide linker. In an scFv-Fc the scFv is connected to the domains of 
the Fc part via a hinge region 
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1.1.2 Antibody generation 
Already in the end of the 19th century, when antibodies had not even been discovered yet, 
Emil von Behring and Shibasaburo Kitasato developed a way to immunize animals for 
production of polyclonal antibody sera for diphtheria and tetanus therapy (von Behring and 
Kitasato, 1890). Despite the fact that the development of the antisera therapy was an enormous 
progress in former times, it has some crucial drawbacks, especially lot to lot inconsistencies 
and adverse effects like serum sickness (Pirquet, 1905). 
In 1975, Köhler and Milstein developed the so called hybridoma technology, a procedure 
which enables the generation and persistent production of monoclonal antibodies in 
hybridoma cells, thus overcoming the reproducibility issues of antibody sera. To obtain 
hybridoma cells, mice are immunized and B- lymphocytes are isolated from the spleen for 
subsequent fusion with immortal myeloma cells. After selection of successfully fused cells, 
single hybridoma clones are screened for secretion of an antibody with the desired properties 
(Köhler and Milstein, 1975). However, also hybridoma technology has some disadvantages, 
like limited number of candidates, inability to provide antibodies against highly conserved 
antigens as well as possible instability of the cell lines. (Bradbury et al., 2018; Kromenaker 
and Srienc, 1994). Furthermore, a recent study revealed that out of 126 hybridoma clones 
analyzed, 31.9 % contained one or more additional productive heavy or light chain which leads 
to issues with specificity and complicates cloning of the ‘right’ genes for the heavy and light 
chain (Bradbury et al., 2018). 
 
1.1.2.1 Generation of monoclonal antibodies by phage display 
In 1990, antibody phage display has been developed, allowing the presentation of antibody 
fragments on phage particles and consequently, the selection of antibody-phage on the basis 
of antigen binding (Barbas et al., 1991; Breitling et al., 1991; McCafferty et al., 1990). Most 
common is the fusion of the antibody to the pIII protein of a filamentous phage (, but also 
fusions to pVII and pIX have been described (Gao et al., 2002; Kwaśnikowski et al., 2005).  
By PCR, VH and VL gene segments are amplified from peripheral blood mononuclear cells 
(PBMCs) and randomly combined by a two-step cloning. This process leads to a stochastic 
combination of heavy and light chains, allowing the construction of antibody libraries with 
more than 1010 different antibodies (Kügler et al., 2015). The VH and VL genes can be either 
directly inserted into the phage genome, or into a specialized vector for phage display, called 
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phagemid. A packaging signal on the phagemid confers its packaging into the phage particle, 
which leads to coupling of genotype and phenotype (Breitling et al., 1991). 
Phage, which present antibodies that bind to an antigen of interest, are separated from non-
binding antibody phage via a procedure that is called panning. A panning round comprises the 
following conceptual steps (Figure 1-3):  
i) coincubation of antibody phage library and antigen 
ii) removing of unbound phage 
iii) elution of bound phage 
iv) amplification of antibody phage using E. coli.  
 
Normally, three rounds of panning are sufficient for a significant enrichment of antigen 
binding phage. To identify monoclonal antibodies with the desired properties, E. coli clones, 
infected with phage from the last panning round, are screened (Russo et al., 2018a).  
In case the scFv-pIII fusion is encoded on a phagemid, an infection with a so called 
helperphage is necessary for phage amplification. The helperphage provides the missing 
genetic information for the remaining phage proteins necessary for phage production; 
furthermore, it carries a mutated M13 ori, therefore the phagemid is preferentially packaged 
into the phage particles during phage amplification instead of the helperphage genome (Vieira 
and Messing, 1987). 
When the M13K07 phage is used to package the phagemids, statistically only one out of ten 
phage particles will carry a scFv-pIII fusion protein on its surface. This is due to a competition 
of wt pIII, encoded on the genome of M13K07 and the fusion-protein pIII which is encoded 
on the phagemid. If a polyvalent display is needed, a so called Hyperphage can be used instead. 
This phage carries a partial deletion of gIII, therefore the sole source of a functional gIII is the 
phagemid. Especially for the first panning round the use of a polyvalent display is 
advantageous and leads to an enhanced enrichment of target specific antibodies. (Rondot et 
al., 2001) 
 




Figure 1-3: Schematic representation of the panning procedure 
A panning consists of the following steps: coincubation of antibody phage library and antigen; removing of 
unbound phage, elution of bound phage and amplification of antibody phage in E. coli after coinfection with a 
helperphage. In the third panning round eluted phage are used for infection and infected E. coli cells are 
separated on agar plates. Subsequently single clones are screened for production of specific scFvs.  
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There are several important advantages of antibody-display methods in comparison to 
hybridoma technology: i) even self-antigens or toxic antigens can easily be used as targets, 
since antibody display circumvents the limitations of the in vivo immune response, ii) due to 
a tight control of the panning conditions, antibodies can directly be selected according to their 
binding properties, like epitope, domain, or even conformation specificity, iii) due to the size 
of the antibody libraries (>1010), more antibody candidates can be included in the selection 
and screening process, iv) antibody phage display does not require animal immunization. 
Therefore phage display became the most widely used in vitro technology for antibody 
generation (Frenzel et al., 2016).  
Instead of antibody fragments other proteins or peptides can be fused to the pIII protein and 
displayed on the phage surface (Smith, 1985), therefore this method can also be used to study 
protein-protein or protein-DNA interactions, to identify immunogenic proteins as potential 
biomarkers or to identify epitopes of antibodies (Becker et al., 2015; Cariccio et al., 2016; 
Kügler et al., 2008; Rebar et al., 1996; Scott and Smith, 1990; Zantow et al., 2016)  
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1.2 Clostridioides difficile and Clostridioides difficile associated disease  
Clostridioides difficile (CDiff) is an anaerobic, rod shaped, gram positive, spore forming, 
toxicogenic, ubiquitous bacterium (see Figure 1-4) that can be detected in soil and water, as 
well as in stool samples of animals and humans (al Saif and Brazier, 1996).  
 
CDiff was firstly described in the 1930ies by Ivan Hall and Elizabeth O’Toole as part of the 
normal gut flora of neonates. Referring to the difficult cultivation under strict anaerobic 
conditions they named it Bacillus difficile (Hall and O’Toole, 1935). In the end of the 1970ies 
CDiff was identified as the causative pathogen of antibiotic treatment associated diarrhea 
(Bartlett et al., 1978), also called Clostridioides difficile associated diarrhea (CDAD). Since 
then, the number of CDiff infections (CDI) has been increasing and in the last two decades 
CDiff even caused epidemic outbreaks (DePestel and Aronoff, 2013; Rupnik et al., 2009). 
Nowadays, the incidence of CDAD in Germany has risen to 5-20 cases per 100.000 per year 
(Burckhardt et al., 2008; Lübbert et al., 2014). Due to its association with antibiotic treatment 
and the resulting high potential for development of antibiotic resistance, the US Centers for 
Disease Control and Prevention (CDC) classifies CDiff as an urgent threat (Centers of Disease 
Control and Prevention, 2013).  
Main risk factors for development of CDAD are hospitalization, advanced age and an impaired 
physiology of the intestine, particularly after antibiotic treatment with Clindamycin, 
Ampicillin or Cephalosporin, or due to other intestinal diseases or surgeries (reviewed in 
Elliott et al., 2007). Furthermore, patients treated with proton pump inhibitors, or non-steroidal 
anti-inflammatories have an increased risk for CDAD (Permpalung et al., 2016; Yearsley et 
Figure 1-4: electron microscopy of Clostridioides difficile;  
Scale bar ≙ 2µm. Source: Norbert Bannert, Kazimierz Madela/ Robert 
Koch Institute 
Dissertation Viola Fühner  Introduction 
9 
 
al., 2006). Another important factor is the state of the immune system: patients with 
immunodeficiency or under immune suppression are more likely to develop CDAD due to an 
impaired humoral immunity (Collini et al., 2012; Lübbert et al., 2013). But recently also more 
and more cases of community acquired CDI have been reported in younger patients without 
the obvious risk factors (Kuijper and van Dissel, 2008). 
Development of CDI is a three step process i) uptake of spores via the fecal oral route ii) 
germination to a vegetative cell and colonization of the intestine iii) amplification and toxin 
production (Rineh et al., 2014) 
The symptoms developed upon CDI cover a broad range of severity and include watery, 
sometimes bloody diarrhea, abdominal pain, fever, leukocytosis, hypalbuminemia, 
pseudomembranous colitis, toxic mega colon, intestinal perforation and sepsis (Robert Koch-
Institut, 2009). The lethality ranges from 2%- 17%, mainly depending on the patients age, and 
the causing Clostridioides difficile strain (Pépin et al., 2005).  
Disease and typical symptoms are only caused by toxigenic strains that carry a pathogenicity 
locus (PaLoc) on their genome (Natarajan et al., 2013). These strains express at least Toxin B 
(TcdB), but most strains express Toxin A (TcdA) and TcdB and some even in combination 
with the binary toxin CDT. Today there are 34 different toxinotypes described that vary in 
gene/protein sequence and/or gene expression (Rupnik et al., 2009; Rupnik and Janezic, 2016). 
In the last two decades the incidence of so called hypervirulent CDiff strains, most of which 
are classified as ribotype 027 strains, has increased. These strains carry mutations within the 
PaLoc, more exactly in the toxin repressor gene tcdc, which may lead to higher toxin 
expression levels and therefore more severe disease (Joost et al., 2009; Razavi et al., 2007). 
 
1.2.1 TcdB, a major virulence factor of Clostridioides difficile 
Together with the binary toxin (CDT), TcdA and TcdB are the main virulence factors of CDiff. 
All three toxins are secreted by the pathogen and are mainly responsible for the symptoms 
attributed to CDAD like destruction of the gut epithelium, leading to watery diarrhea and 
pseudomembranous colitis (Chandrasekaran and Lacy, 2017; Gerding et al., 2014; Just et al., 
1995a, 1995b; Rupnik et al., 2009). 
TcdA and TcdB are huge single-chain multidomain proteins consisting of the following 
functional domains: glucosyltransferase domain (GTD), cysteine protease domain (CPD), 
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translocation domain (TLD) and Combined Repetitive Oligo Peptides (CROPS)-domain. A 
schematic representation of TcdB is given in Figure 1-5. 
The N- terminal glucosyltransferase domain (TcdB AA1-543) is the actual toxic cargo, that 
acts on small Rho-GTPases within the cytosol of the host’s cells. It transfers a glucose moiety 
from a uridine-diphosphate to threonine (Thr) 37 or Thr 35 in the switch I region of small 
Rho-GTPases like RhoA, RhoB, RhoC, RhoG, Rac1-3, Cdc42, and TC10 (Busch et al., 1998; 
Just et al., 1995a). Due to the glucosylation, the GTPases are trapped in an inactive state, which 
inhibits multiple signaling events in the host cell. One consequence that is easily observable 
is the breakdown of the actin cytoskeleton, leading to cell rounding (Just et al., 1995a).  
 
 
Amino acids 543-767 build up a cysteine protease domain that catalyzes the proteolytic 
auto-processing, that releases the GTD into the cytosol upon translocation. To prevent 
premature cleavage of the GTD, the cysteine protease domain requires activation induced by 
allosteric binding of cytosolic Inositol-hexakisphosphate (InsP6) (Egerer et al., 2007, 2009).  
The domain C-terminal of the cysteine protease is designated as the translocation domain 
(AA768-1852). It is the largest segment of TcdB and comprises almost 50% of the toxin. 
Nevertheless, exact information about the function and the molecular mechanisms involving 
this huge domain are still elusive, although notably progress had been made during the last 
CPD GTD TLD N CROPs C 
Figure 1-5: Schematic representation of TcdB: 
A) Domain organization of TcdB: GTD= glucosyltransferase domain; CPD= cysteine protease domain;    
TLD= translocation domain and CROPs = combined repetitive oligo peptides 
B) 3D model of TcdB without the CROPs based on a X-ray crystallography 3D structure of TcdA generated 
using swiss model. The colors are matching the schematic representation.  
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years. The TLD includes a stretch of amino acids (AA 830-990) which are proposed to be 
involved in pore formation for translocation of the N-terminal portion of the toxin across the 
endosome membrane upon acidification (Genisyuerek et al., 2011). Recently, three putative 
receptor binding regions of TcdB have been identified that are located within this domain. 
These interact with chondroitin sulfate proteoglycan 4 (PSPG4), polio virus receptor like 3 
(PVRL3) or members of the frizzled protein family. The relevance of each single receptor in 
the course of the disease is still object of discussion (Chen et al., 2018; Gupta et al., 2017; 
LaFrance et al., 2015; Tao et al., 2016; Yuan et al., 2015).  
The C-terminus of TcdA and TcdB is composed of repetitive elements, where long and short 
repeats are combined in so called Combined Repetitive Oligo Peptides (CROPS). In case of 
TcdA the CROPs interact with carbohydrate structures [α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAc] 
on the cell surface of the target cells, mediating a first contact between toxin and target cell 
(Greco et al., 2006) and, furthermore, prevent premature auto-proteolytic cleavage of the toxin, 
by stabilization of its conformation (Olling et al., 2014). For TcdB the role of the CROPS is 
less defined, but due to the homology of the two toxins similar functions can be assumed. For 
both toxins it had been shown, that toxicity is at least partially preserved in CROP deletion 
mutants (Frisch et al., 2003; Manse and Baldwin, 2015; Olling et al., 2011). This finding 
stresses the importance of the receptor binding regions located within the TLD. 
  
Figure 1-6: Schematic representation of the multistep intoxication mechanism by TcdB  
1)Binding to several cell surface receptors (violet) via the CROPs (green) and the TLD (blue); 2) receptor 
mediated endocytosis; 3) acidification of endosomes; 4) conformational change and translocation of GTD 
(red) and CPD (grey) through the translocation pore 5) inositol hexakisphosphate induced autoproteolysis 
and 6) transfer of glucose moieties (orange) from UDP-glucose to small GTPases (beige). Figure adapted 
from Chandrasekaran and Lacy, 2017  
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Taken together, the functions of the single domains allow the conclusion of an intoxication 
with a multistep mechanism (Figure 1-6), involving the following steps: (1) cell/receptor 
binding, (2) endocytosis, (3) conformational change upon acidification of the endosome, (4) 
pore formation and translocation across the endosomal membrane, (5) auto processing and 
release of the enzymatic domain into the cytosol, (6) glucosylation of host GTPases. 
(Chandrasekaran and Lacy, 2017) 
 
1.2.2  Current therapies for clostridium difficile associated disease 
CDI is treated in an evidence based manner, depending on the severity of infection and 
symptoms. (Lübbert et al., 2014). Standard therapy for mild to moderate CDI provides, that 
treatment with the causative antibiotic is interrupted (when possible) and CDiff is directly 
targeted with the more specific antibiotics metronidazole, vancomycin or fidaxomicin (Bolton 
and Culshaw, 1986; Goldstein et al., 2012; Tedesco et al., 1978). However, antibiotic therapy 
presumably further disrupts the gut microbiota that confers colonization resistance against 
CDiff. Hence, in 20% -30% of CDI cases antibiotic therapy is not successful, or amelioration 
is only of temporary nature. These patients develop recurrences of CDI within two to six weeks 
after completion of antibiotic treatment (Pépin et al., 2006). Another concern about antibiotic 
therapy is the high potential of CDiff to evolve resistances (Centers of Disease Control and 
Prevention, 2013; Gao and Huang, 2015), therefore alternative therapy approaches are 
urgently needed. 
One such alternative is stool transplantation or microbiome transfer. Up to now this form of 
therapy is still regarded as experimental, even though it gained particular attention because of 
the promising response rate of 89% in patients with recurrent CDI (Lübbert et al., 2014). 
However, long term risks of stool transplantations are still unknown, since there are numerous 
studies that indicate a linkage between the state of the intestinal microbiome and the 
development of diverse diseases e.g. autoimmune diseases, diabetes mellitus and obesity 
(Barlow et al., 2015; Hong et al., 2010; Karczewski et al., 2014; Rogers, 2015) therefore this 
therapy is only applicable to patients with multiple relapses (Lübbert et al., 2014).  
Since the severe damage of the gut mucosa is mainly caused by TcdA and TcdB further therapy 
approaches directly target the toxins, either one or both. One example is Tolevamer, a 
non-antibiotic, toxin binding anionic polymer (>400 kDa) that binds to TcdA and TcdB in a 
non-covalent manner. But even though Tolevamer was able to neutralize TcdA and TcdB in 
an in vitro assay and prevented CDI in a hamster model, the clinical success of Tolevamer was 
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inferior to both metronidazole and vancomycin in two multinational randomized Phase III 
trials (Johnson et al., 2014; Kurtz et al., 2001).  
The two toxins have also been exploited for vaccine development in several studies. Active 
immunization with toxoids, toxin fragments or chimeric toxins fragments induces a protective 
immune response in animal models (mouse and hamster) (Kim et al., 1987; Leuzzi et al., 2013; 
Wang et al., 2012). Toxoids of TcdA and TcdB have also already been proven to elicit toxin 
neutralizing serum antibody responses in humans (Kotloff et al., 2001). Furthermore, 
vaccination with toxoids led to resolution of recurrent CDAD in three patients with a history 
of 7-22 month of recurrent CDAD episodes (Sougioultzis et al., 2005). To date a placebo-
controlled, randomized, observer-blinded clinical phase three study using a toxoid based 
vaccine is ongoing (Clostridium Difficile Vaccine Efficacy Trial - ClinicalTrials.gov). 
However, up to date there is no CDiff toxin based vaccine approved yet and furthermore, due 
to immunosenescence in elderly people, active immunization might be less efficient in the part 
of the population that is at particular risk of developing CDI upon hospitalization and antibiotic 
therapy (Pera et al., 2015).  
Alternatively, passive immunization strategies might be used to prevent recurrence or even 
development of CDAD. Indeed, in October 2016 the monoclonal human antibody, 
Bezlotoxumab, has been approved for therapy of recurrent CDAD by the U.S. Food and Drug 
Administration (FDA). Bezlotoxumab is directed against the N-terminal portion of the CROPs 
of TcdB and blocks binding of TcdB to the target cells either by inhibition of binding to the 
cell surface carbohydrate structures, or by inhibition of binding to CSPG4 receptor (Babcock 
et al., 2006; Gupta et al., 2017; Orth et al., 2014). In two double-blind, randomized, placebo-
controlled, phase 3 trials, MODIFY I and MODIFY II, combining antibiotic therapy with 
administration of Bezlotoxumab reduced the recurrence rate from 28% to 17% (MODIFY I) 
and from 26% to 16% (MODIFY II) (Wilcox et al., 2017). Nevertheless, due to the increasing 
number of toxinotypes (Rupnik and Janezic, 2016) that might not all be vulnerable to 
Bezlotoxumab as well as the limited efficacy, there is still room for improvement. 
Improvement could be achieved using defined combinations of antibodies, targeting different 
epitopes of TcdB at the same time. Also a better understanding of the toxins function and 
epitopes that might convey neutralization is needed for a more rational antibody generation 
strategy and/or vaccine design. 
  




Aim of the work was to use an antibody phage display approach to generate a panel of 
monoclonal human antibodies against TcdB. After conversion into scFv-Fc format, the 
binding properties and epitopes of the antibody candidates as well as the neutralization 
potential should be determined. By correlating the neutralization efficacy with the epitopes 
found for the respective antibodies, this work will provide valuable knowledge for future 
development of therapeutic antibodies against TcdB and rational vaccine development 
strategies.
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2 Materials and Methods 
2.1 Materials 
2.1.1 Consumables 
The consumables used in this study are listed in Table 2-1. 
 
Table 2-1: Consumables  
Consumables  Manufacturer 
24 well Polypropylene Plate  Sarstedt, Nürmbrecht  
Air-o-Seal hydrophobic Gas permeable seal 4titude, Dorking, UK 
Amicon Ultra Centrifugal filters 30K  Merck Millipore KGaA, 
Burlington, USA 
Blotting paper (550 g/m2) Sartorius, Göttingen 
Cannula B. Braun International GmbH, 
Melsungen 
Costar Microtiter-plate 96 well polystyrene  Corning Inc., New York, USA 
Cryo tube vials (2 mL)  Nunc/ Thermo Scientific 
Disposable Cuvettes Brand, Wertheim 
Disposable spatula (L-shape)  VWR, Darmstadt  
Electroporation cuvettes, GenePulser 0.1 cm  Bio-Rad Laboratories, München 
Filter (0,45 μm, 0,2 μm)  Sartorius, Göttingen  
Filter paper (3mm) Bio-Rad, München 
Inoculation loops VWR, Darmstadt 
MabSelect SuRe Protein A affinity matrix GE Healthcare, Freiburg 
Microtiter-polypropylene plate 96 well, U-shape Greiner Bio-one, Frickenhausen  
Multiply-μStrip Pro 8-strip Sarstedt, Nümbrecht 
Parafilm American National Can, Chicago, 
USA  
Pasteur pipettes (3 mL)  Hartenstein, Würzburg 
PCR- Reaction-tube Greiner Bio-one, Frickenhausen  
Petridishes 70x20 mm; 150x20 mm Greiner Bio-one, Frickenhausen  
Pipette Tips (10 μL, 200 μL, 1000 μL, 5000 μL)  Sarstedt, Nürmbrecht  
Pipette tips, filtered (10 μL, 200 μL, 1000 μL)  Sarstedt, Nürmbrecht  
Polypropylene centrifugation tubes (15 mL, 50 mL) Corning Inc., New York, USA 
Polystyrene tissue culture flask T75, canted neck, 
vented cap 
Corning Inc., New York, USA 
Polystyrene tissue culture plate 96x wells  
CELLSTAR 
Greiner Bio-one, Frickenhausen  
PVDF membrane Carl Roth, Karlsruhe 
Reaction tubes (1,5 mL, 2 mL)  Sarstedt, Nürmbrecht  
Serological pipets (2 mL, 5 mL, 10 mL, 25 mL)  Sarstedt, Nümbrecht  
Screw lid micro caps 2 mL Sarstedt, Nümbrecht 
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Consumables  Manufacturer 
Syringe Inject  B. Braun International GmbH, 
Melsungen 
Unifilter (10 mL) GE Healthcare, Freiburg 
Uniplate PP (10 mL) GE Healthcare, Freiburg 
Whatman filter paper GE Healthcare, Freiburg 
Whatman syringe filter, 0.45 μm GE Healthcare, Freiburg 
Zeba™ Spin Desalting Columns, 89892  Thermo Fisher Scientific Inc., 
Waltham, USA. 
 
2.1.2 Technical devices 
The technical devices used in this study are listed in Table 2-2. 
Table 2-2: Technical devices 
Device Model Manufacturer 
Blot-Apparatus  
TransBlot Turbo; Semi-
Dry Transfer Cell  
BioRad, München  
Centrifuges  
5415D, 5804R and 
5810R 
Eppendorf, Hamburg  
Multifuge 3 S-R Heraeus, Hanau 
Sorvall RC5 
Thermo Fisher Scientific 
Inc., Waltham, USA 
Sorvall RC5B Plus 
Thermo Fisher Scientific 
Inc., Waltham, USA. 
Electrophorese-chamber 
(Agarose gels) 
PerfectBlue Mini S PeqLab, Erlangen 
Electrophorese-chamber (SDS 
gels)  
Mini Protean III cell  BioRad, München  
Electroporation device Micro Pulser™ BioRad, München 
ELISA-readers  
Tecan Sunrise  Tecan, Crailsheim  




Tecan, Crailsheim  
Columbus, Pro Tecan, Crailsheim 
Columbus, Plus Tecan, Crailsheim 
Gel documentation  ChemiDoc MP  BioRad, München 
Incubators  
BE400 Memmert, Schwabach 
Certomat® BS-1 Sartorius, Göttigen 
Infors Multitron HT, 
Minitron HT 
Infors HT, Einsbach 
Hera Cell  Heraeus, Hanau 
Laminar flow bench MSC-Advantage 
Thermo Fisher Scientific 
Inc., Waltham, USA. 
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Device Model Manufacturer 
Laminar flow bench Herasafe  Heraeus, Hanau  
Microscopes 
Eclipse TS100 Nikon, Minato, Japan 
Axiovert 200 Carl Zeiss, Oberkochen 
Mixing device Vortex Genie 2  
Scientific Industries,  
New York, USA 
MTP-shake incubator Vortemp56  
Labnet International, Inc, 
Edison, USA 
pH-Meter CG810 Schott, Mainz 
Photometer Libra S11 Biochrom, Berlin 
Pipettes 
Research Eppendorf, Hamburg  
Biohit eLine Sartorius, Göttingen 










Protein purification system Profinia BioRad, München 
Spectrophotometer  ND1000  PeqLab, Erlangen  
Thermocycler  
DNA Engine  
MJ research PTC-200 
Minicycler™ 





Mixing block MB-102 Bioer, Hangzhou, China 
Scale 
Laboratory LC 2200 S,  
E 1200 S, A120 S  
Sartorius, Göttingen  
 
Sonicator Bioruptor® Pico  Diagenode, Denville, USA 
Waterbath Waterbath GFL Laborbedarf, Braunschweig 
Water purification system Arium 611  Sartorius, Göttingen  
 
2.1.3 Chemicals 
All chemicals used in this project were purchased from following suppliers: ApplChem GmbH 
(Darmstadt, Germany), Carl Roth GmbH (Karlsruhe, Germany), Merck KGaA (Darmstadt, 
Germany), Roche Diagnostics GmbH (Penzberg, Germany), SERVA Electrophoresis GmbH 
(Heidelberg, Germany) and Sigma-Aldrich Chemie GmbH (Steinheim, Germany)  
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2.1.4 Bacteria strains, phage and cell lines 
All bacteria strains, phage and cell lines used in this study are listed in Table 2-3. 
Table 2-3: Bacteria strains, phage and cell lines  
Strain Genotype/ description Application Source 
E. coli TG1 K-12 supE thi-1 _(lac-proAB) 
_(mcrB-hsdSM)5, (rK-mK-) F' 
[traD36 proAB+ lacIq 
lacZ_M15] 
Panning GE Healthcare, 
Freiburg 





endA1 supE44 thi-1 recA1 
gyrA96 relA1 lac [F′ proAB 
lacIqZΔM15 Tn10 (Tetr)] 
Panning and 
cloning 
Stratagene, LA Jolla, 
USA 
E. coli  
TOP10F’ 
F'[lacIq Tn10(tetR)] mcrA 
Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 deoR 
nupG recA1 araD139 Δ(ara-
leu)7697 galU galK 






M13K07 wt Phage 
production 
(Vieira and Messing, 
1987) 
Hyperperphage M13K07ΔgIII Phage 
production 
(Rondot et al., 2001) 
Vero Cells African green monkey kidney 
epithelial cell line, adherent 
Cell rounding 
assay 
MHH Hannover, Inst. 
f. Toxikologie 
HEK293-6E Human embryo kidney cell 









Derived from HEK293-6E 








2.1.5 Plasmids  
The plasmids used in this study are listed in Table 2-4.  
Table 2-4: Plasmids  
Plasmid Description Reference 
pHAL30 Phagemid, coding for scFv:pIII fusion proteins; 
library Vector for HAL9/10 naïve human 
antibody libraries 
 (Kügler et al., 2015, 9) 
pHORF3 Phagemid, coding for oligopeptide:pIII fusion 
proteins, library vector for ORFeome or single 
gene –fragment display libraries 
(Kügler et al., 2008) 
pCSE2.6-
hIgG1-Fc 
Plasmid for scFv-Fc production in mammalian 
cell culture 
(Beer et al., 2018; Russo et 
al., 2018b) 
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2.1.6 Kits  
Kits were used for DNA purification from PCR mixes or E. coli cultures. An overview of the 
kits used in this study is given in Table 2-5. 
Table 2-5: Molecular-biological kits 
Kit Application Manufacturer 
Hi Yield® Gel/PCR DNA 
Fragment Extraction Kit,  
DNA Purification SLG; Süd-Laborbedarf 
Gauting 
Fast DNA End Repair Kit Generation of blunt ends 
after DNA sonication 
Thermo Fisher Scientific 
Inc., Waltham, USA 
NucleoSpin® Gel and  
PCR Clean-up  
DNA Purification Macherey-Nagel, Düren 
NucleoSpin® Plasmid  Plasmid extraction Macherey-Nagel, Düren 
NucleoBond Xtra Midi, Plasmid extraction Macherey-Nagel, Düren 
 
2.1.7 Antibodies 
In ELISA, Immunoblots or peptide arrays, enzyme or fluorochrome coupled antibodies were 
used as detection system. A list of antibodies used is given in Table 2-6 
Table 2-6: Antibodies 
Antibody  Description  Manufacturer 
A0168 Goat anti-mouse IgG (Fc specific) HRP 
conjugated 
Sigma Aldrich, München 
A0170 Goat anti-human IgG (Fc specific) HRP 
conjugated 
Sigma Aldrich, München 
9E10 Mouse anti-c-myc-tag AG Dübel, Braunschweig 
A80-304D6 Anti-human IgG-Fc Fragment; cross-
adsorbed DyLight® 680 conjugated 
Bethyl Laboratories Inc. 
Montgomery, USA 
12CA5 Anti-HA Peptide ReadyTag Mouse 
IgG2b  
Bio X Cell, West Lebanon, 
USA 
5470S Polyclonal anti-Mouse IgG (H+L) 
DyLight® 680 conjugated 




Oligonucleotides were used as primers for DNA amplification in colony PCR as well as 
standard PCRs. All oligonucleotides use this work are listed in the following Table 2-7. 
 
Table 2-7: Oligonucleotides 
Name  ID Sequence (5’-3’) Application 
MHgIII-r 11 CTAAAGTTTTGTCGTCTT
TCC 
Colony PCR on pHAL30, 
pHORF3, sequencing 




410 CACTTTGCCTTTCTCTCC Colony PCR on pCSE2.6-
hIgG1-Fc-XP 
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Amplification of tcdB gene 
from genomic DNA 
ViF218-TcdB-rev 3082 CTATTCACTAATCACTAA
TTGAGCTGTATCAGG 
Amplification of tcdB gene 
from genomic DNA 
 
2.1.9 Enzymes  
Enzymes (polymerases, restriction enzymes, proteases and ligases) used in this study are 
listed in Table 2-8. 
 Table 2-8: Enzymes  
Name Application  Manufacturer 
GoTaq® DNA-
Polymerase 
Colony PCR Promega (Mannheim, DE)  
NcoI HF restriction of DNA New England Biolabs (Frankfurt 
a. M., DE) 
NotI HF restriction of DNA New England Biolabs (Frankfurt 
a. M., DE) 
PmeI HF digestion of pHORF3 
Vector  
New England Biolabs (Frankfurt 
a. M., DE) 
Phusion DNA-Polymerase  Amplification of tcdB 
gene 
New England Biolabs (Frankfurt 
a. M., DE)  
T4 DNA Ligase Ligation of inserts into 
vector backbones 
Promega (Mannheim, DE)  
Trypsin Elution of phage Sigma-Aldrich (Taufkirchen, DE) 
Trypsin/EDTA Cell passaging Biochrom 
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2.1.10 Media, Supplements and Buffers  
The media and supplements used for cultivation of mammalian cells or E. coli are listed in 
Table 2-9, Table 2-10 and Table 2-11. 
Table 2-9: Media and solutions for cultivation of mammalian cells 
Media/Solution Application Manufacturer 
RPMI1640 cultivation of Vero cells Merck Biochrom GmbH, 
Berlin 
L-Glutamine media supplement for 
cultivation of Vero cells (2 
mM),HEK293-6E and 
Expi293F cells (8 mM) 
Merck Biochrom GmbH, 
Berlin 
FBS superior  
(Fetal bovine serum)  
cultivation of Vero cells Merck Biochrom GmbH, 
Berlin 
TRYPSIN/EDTA  
(0,05 %/0,02 %) in PBS, 
w/o Ca2+, Mg2+ 
detachment of Vero cells 
for passaging  
Merck Biochrom GmbH, 
Berlin 




Thermo Fisher Scientific Inc., 
Waltham, USA 
Pluronic-F68  anti-foam agent PAN-Biotech GmbH, 
Aidenbach 
TN1 (Tryptone N1) supplement for boosting 
yields of human cell 
cultures 
Merck Biochrom GmbH, 
Berlin 
HEK TF Expi293F production media XELL AG, Bielefeld 
HEK FS supplement for boosting 
yields of human cell 
cultures 
XELL AG, Bielefeld 
 
Table 2-10: Media used for E. coli cultivation 
Basic Media Composition  
2x YT Media 1 % (w/v) Bacto-Yeast Extract 
1.6 % (w/v) Bacto-Tryptone 
0.5 % (w/v) NaCl 
SOC Media 0.5 % (w/v) Bacto-Yeast Extract 
2.0 % (w/v) Bacto-Tryptone 
0.05 % (w/v) NaCl 
1.8 % (w/v) Glucose 
 
Table 2-11: Supplemented media used for E. coli cultivation and selection 
Supplemented Media Supplements 
2x YT- A 100 μg/mL ampicillin 
2x YT- GA 100 mM glucose, 100 μg/mL ampicillin 
2x YT- AK 100 μg/mL ampicillin, 50 μg/mL kanamycin 
2x YT- T 20 μg/mL tetracycline 
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In Table 2-12 the compositions of buffers and solutions used are listed. 
Table 2-12: Composition of buffers and solutions  
Application Description Composition 
DNA gel 
electrophoresis 


















TAE buffer (solvent) 
Agarose 
Ethidium bromide 





































Coomassie Brilliant Blue R250 
Acetic acid 
2-Propanol 































Stopping solution (solvent) 
Na2CO3 
37% Formaldehyde 
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Peptide array  
Fluorescent 
blocking buffer purchased from Rockland, Limerick, USA 
 
If not mentioned otherwise, water was used as solvent and the pH was adjusted with 
1 M HCl and 1 M NaOH. 
 
2.1.11 Software 
The software used is listed in Table 2-13. 
Table 2-13: Software 
Software Application  Reference 
Image Lab  ChemiDoc MP image processing Bio-Rad 
VBase2 Analysis of antibody sequences (Mollova et al., 2010) 
ImageJ Cell counting Wayne Rasband (NIH) 
PyMol v1.3 visualization of protein 3D 
structures 
The PyMOL Molecular Graphics 
System, Schrödinger, LLC. 
PepSlide®  Analysis of the peptide array Sicasys software GmbH 
SWISS-
MODEL 
Protein structure homology 
modelling 
(Waterhouse et al., 2018) 
NCBI  Literature, Protein- and Gene-
sequences  
http://www.ncbi.uhm.nih.gov  
Microsoft office Text and Data editing https://de.libreoffice.org 
Inkscape 0.91 Figures  https://inkscape.org/ 








2.2.1 Molecular biological methods  
2.2.1.1 DNA preparation 
Plasmid DNA was isolated from E. coli overnight cultures with commercial plasmid DNA 
preparation kits (NucleoBond Xtra plasmid Midiprep or NucleoSpin Plasmid Miniprep Kit 
Macherey&Nagel) according to their manuals.  
PCR-products or products of enzymatic plasmid digestion were either purified directly from 
the reaction mix or from agarose gels after electrophoresis with a commercial PCR clean up 
and gel extraction kits (NucleoSpin Gel and PCR clean-up, Macherey&Nagel or Hi Yield® 
Gel/PCR DNA Fragment Extraction Kit, SLG). The DNA was eluted or solubilized with 
ddH2O and stored at -20 °C. 
2.2.1.2 Photospectrometric determination of DNA concentration  
To determine the concentration of DNA preparations the absorbance at λ = 260 nm was 
measured using a spectrophotometer. The following formula was applied to calculate the 
concentration: A260 = 1 ≙ 1 ng µL-1. 
2.2.1.3 Agarose gel electrophoresis  
A 1% Agarose gel was placed inside an electrophoresis chamber and the chamber was filled 
with 1x TAE buffer. DNA samples were mixed with 6x loading dye and loaded onto the gel. 
After separation of DNA fragments at 110 V for 25-30 min. The gel was documented using 
UV radiation in the ChemiDoc™ (BioRad) imaging system. 
2.2.1.4 DNA sequencing  
To control cloning, analyze clones obtained from phage display or characterize the TcdB-
gene-fragment library Sanger sequencing was performed.  
Sequencing of purified plasmids or PCR products was carried out by Seqlab Sequence La-
boratories GmbH (Göttingen, Germany). 
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2.2.1.5 Polymerase chain reaction  
The DNA amplification by PCR was performed to control cloning success, to analyze clones 
after panning or to amplify genes from genomic DNA of Clostridioides difficile. 
2.2.1.6 Colony PCR  
Colony PCR was performed either after panning to verify that obtained E. coli clones contain 
pHAL30 plasmids with complete scFv genes (VH and VL inserts), or to control cloning success 
after transformation of ligated plasmids into E. coli. DNA was amplified using primers 
flanking the cloning sites of the vectors (Primers 11 and 125 for pHAL30 or pHORF3 and 
primers 410 and 411 for pCSE2.6 vectors). A small amount of E. coli cells was added as DNA 
template to the reaction mix. The reaction mix (Table 2-14) was incubated in a thermocycler 
with the appropriate temperature program (Table 2-15). After the PCR, the reaction mix was 
analyzed by agarose gel electrophoresis. 
Table 2-14: Reaction mix for colony PCR 
Stock solution 
Volumes [µL] per 10 µL 
reaction mix 
5x Green GoTag Reaction 
Buffer 
2.0 
25 mM MgCl2 0.4 
10 mM dNTP mix 0.2 
10 mM forward primer 0.5 
10 mM reverse primer 0.5 





Table 2-15: Temperature program for colony PCR 
Step Temperature [ °C] Time [s] Repeats 
1. Initial denaturation 94  180 x1 
2. Denaturation 94  40 
x25 3. Annealing 52  20 
4. Elongation 72  30/kb 
5. Final Elongation 72 600 x1 
6. Store 16  forever  
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2.2.1.8 Amplification of tcdB gene  
For generation of a TcdB gene fragment library, the tcdB gene had to be amplified from ge-
nomic DNA isolated from Clostridioides difficile strain 630 by PCR, as described in Table 
2-16 and Table 2-17. To avoid mutations in the gene the Phusion DNA polymerase which has 
a lower error rate of 4.4x10-7 was used. 
Table 2-16: Reaction mix for PCR 
Component Volume [µL]  
5x Phusion Buffer  20 
10 µM Primer ViF218-TcdB-for  5 
10 µM Primer ViF218-TcdB-rev 5 
dNTPs 10mM 3 
Phusion polymerase 2U /µL 1 
Genomic DNA  1,34 (≙ 250 ng) 
dH2O 64,66 
 
DNA was amplified in 25 temperature cycles using the following program. 
Table 2-17: Temperature program for PCR  
Step  Temperature [ °C] Time [s] Repeats 
1 98 30 1x 
2 98 10 25x 
3 64 / 67 20 
4 72 285 
5 72 300 1x 
6 16 For ever 1x 
 
Success of DNA amplification was verified by Agarose gel electrophoresis 
2.2.1.9 DNA cloning  
2.2.1.9.1 Cloning of scFv DNA fragments from pHAL30 to pCSE2.6  
For production of antibodies as scFv-Fcs in mammalian cells the scFv-coding DNA segment 
had to be cloned into the pCSE2.6-hIgG1 –XP vector. For this purpose, 1 µg scFv containing 
pHAL30 was digested with NcoI and NotI (20 U each) for 90 min at 37 °C according to 
manufacturer’s instructions. After the separation of the DNA fragments by agarose gel 
electrophoresis, the scFv-DNA was extracted from the gel and purified as described in 2.2.1.1 
The pCSE2.6-hIgG1-Fc-XP vector backbone was NcoI and NotI digested, too and directly 
purified. Concentration of vector backbone and insert DNA was determined. A threefold molar 
excess of scFv-DNA was ligated into the vector using 1 U T4 ligase (Promega) according to 
manufacturer’s instructions. Ligation mix was heat inactivated and 2 µL were used for heat 
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shock transformation of E. coli. Success of cloning was verified by colony PCR (see 2.2.1.6) 
and DNA sequencing (see 2.2.1.4) 
2.2.1.9.2 Cloning of tcdB single gene library using pHORF3 
For cloning of tcdB single gene library the tcdB gene was amplified from genomic DNA as 
described in 2.2.1.7. Success of PCR was confirmed by agarose gel electrophoresis and PCR 
product was purified from the gel as described in 2.2.1.1. The PCR product (1,25 µg) was 
diluted in 100 µL ddH2O and fragmented using Bioruptor® Pico sonicator (Diagenode) using 
following settings: 45 cycles, 30 s sonication at low intensity, 30 s pause. Sample was chilled 
in a 4 °C waterbath throughout fragmentation process. Fragmented DNA was concentrated 
using Amicon Ultra Centrifugal filters (30K; Millipore). Blunt ends were generated using the 
Fast DNA End Repair Kit (Thermo Fisher Scientific Inc., Waltham, USA) according to 
manufacturer’s instructions. DNA product was purified as described in 2.2.1.1. Afterwards, a 
10-fold molar excess of gene fragments were ligated into PmeI digested and CIP treated 
pHORF3 (see also Table 2-18). The ligation mix was incubated at 16 °C overnight. 
Table 2-18: composition of ligation mix 
Component Volume 
pHORF3 cut pmeI/CIP  3,5 µl (≙ 1000 ng) 
Fragmented tcdB  7,6 µl (≙ 360 ng) 
Ligase Buffer (10x) 10 µl 
Promega T4 DNA Ligase (3 U/µl) 3,33 (≙ 10U) 
dH2O 75,5 
 
To get rid of salts interfering with E. coli transformation by electroporation, ligation mix buffer 
was exchanged to H2O using Amicon Ultra Centrifugal filters (30K von Millipore).  
Electro competent TOP10F’ cells were thawed on ice. Twenty-five µL of cells were mixed 
with 175 ng ligated DNA in 5µL ddH20 and transferred into a pre-chilled (4 °C) 
electroporation cuvette. Electroporation was performed using a 1,8 kV pulse in the Micro 
Pulser™ device. One mL prewarmed (37 °C) SOC media was immediately added and the cells 
were transferred into reaction tubes. After an incubation at 650 rpm and 37 °C for 1 hour cells 
were plated on 2xYT-GA-agar in a square dish. After incubation at 37 °C overnight 25 mL of 
2x YT media was added to the plates and the colonies were scraped off using a glass spatula. 
20 % (v/v) glycerol was added to the bacteria suspension. After transferring to screw lid tubes 
the library was shock frozen in liquid nitrogen and stored at -80 °C. 
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2.2.2 Bacterial cultivation techniques  
2.2.2.1 Sterilization  
All materials, media and solutions used for sterile work, were autoclaved at 121 °C for 20 min. 
Heat sensitive substances were sterilized by filtration through 0,2 µm pore filters. 
2.2.2.2 Storage of E. coli  
For long term conservation, aliquots of E. coli overnight cultures, or dense E. coli cultures 
were supplemented with 20% glycerol (v/v) and stored at -80 °C. 
Liquid cultures or colonies on agar plates were stored at 4 °C for shorter time periods of up to 
one week. 
2.2.2.3 E. coli transformation  
For transformation of E. coli two different techniques were used. For simple cloning of inserts 
from one vector backbone to another heat shock transformation was performed. For cloning 
of libraries, transformation rates normally obtained by heat shock transformation are not 
sufficient, therefore electroporation was used for this purpose (see 2.2.1.9.2). 
2.2.2.3.1 Transformation by heat shock  
25 µL of chemically competent cells were slowly thawed on wet ice. The cells were mixed 
with 2 µL of heat inactivated ligation mix and incubated on ice for 15 min. After a 42 °C heat 
shock for 1 min. cells were directly placed back into the ice bath for another two min. 
Prewarmed SOC media (250 µL) was added and the cells were incubated at 37 °C and 650 
rpm for 30 min. The cell suspension was plated on prewarmed 2xYT-G-agar, supplemented 
with the proper antibiotic and incubated overnight at 37 °C. 
2.2.2.4 Production of soluble scFv in E. coli in MTP 
The cavities of a U-shape 96 well polypropylene plate were filled with 150 µL 2xYT-GA 
media. Each well (except of one negative control well) was inoculated with an E. coli clone 
containing a pHAL30 plasmid with an scFv insert. E. coli clones were incubated overnight at 
37 °C at 800 rpm in a Vortemp56 incubator. This plate is referred to as the master plate.  
The cavities of a new U-shape 96 well polypropylene plate were filled with 150 µL 2xYT-GA 
media and each well was inoculated with 10 µL of the overnight culture from the 
corresponding well of the master plate. The fresh cultures were incubated for ~1,5 h at 37 °C 
and 800 rpm until an O.D.600 nm of 0,5 was reached. The cells were pelleted by centrifugation 
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and the old media was removed. The cell pellets were resuspended in 150 µL 2xYT-A media 
containing 50 µM Isopropyl-β-D-thiogalactopyranosid (IPTG) to induce the LacZ promoter 
and start the scFv production. After overnight incubation at 30 °C and 800 rpm the cells were 
pelleted and the scFv containing supernatant was harvested. 
 
2.2.3 Phage handling 
2.2.3.1 Packaging of peptide libraries with Hyperphage 
For ORF enrichment and to package the pHORF3-TcdB-gene fragment library into phage 
particles with polyvalent display, Hyperphage was used for infection. 
An aliquot of the TcdB-single gene library was used to inoculate 400 mL of 2xYT media to 
an O.D.600 nm of 0,1. Cells were incubated at 37 °C and 250 rpm in an Infors Multitron HT 
incubator until an O.D.600 nm 0,5 was reached.  
Since the cells still lack the genetic information for the phage coat proteins, infection with 
M13K07ΔgIII “Hyperphage” was performed: 25 mL of the cell suspension were transferred 
to a 50 mL Falcon tube, mixed with 20 multiplicity of infection (MOI) Hyperphage 
(M13K07ΔgIII) and incubated 30 min at 37 °C without shaking. After 30 min of incubation 
at 37 °C at 250 rpm to express the kanamycin resistance, cells were pelleted 10 min at 3220 xg 
and transferred to 400 mL of 2xYT-AK media. TcdB-Fragment-phage were produced >20h at 
30 °C and 250 rpm in an Infors Multitron HT incubator.  
The phage particles were harvested from the cultivation slurry by a two-step precipitation. 
Therefore, the bacteria were pelleted by centrifugation at 10.000 xg for 30 min in a pre-chilled 
centrifuge and the supernatant was transferred into a fresh vessel. The phage particles were 
precipitated at 4 °C overnight by adding 1/5 volume phage precipitation buffer (PEG-NaCl). 
The precipitated phage particles were pelleted by 1h centrifugation at 12.000 xg and 4 °C 
(Sorval Centrifuge RC5B Plus, Rotor F9S) and resuspended in 10 mL phage dilution buffer 
(PDB). To increase purity, the phage were filtered (Whatman syringe filter, 0.45 μm) and 
again 1/5 volume of phage precipitation buffer was added for the 2nd phage precipitation (2h 
on ice). Phage were pelleted for 30 min at 20.000 xg and 4 °C (Sorval Centrifuge RC5B Plus, 
Rotor SS34) and resuspended in 1 mL of PDB. Remaining E. coli cells were pelleted for 2 min 
at 16,100 xg and TcdB-fragment phage libraries were collected and stored at 4 °C. 
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2.2.3.2 Production of monoclonal phage in MTP 
The cavities of a U-shape 96 well polypropylene plate were filled with 150 µL 2xYT-GA 
media. Each well (except of one negative control well) was inoculated with an E. coli clone 
containing a pHORF3 plasmid with a tcdB gene fragment insert. E. coli clones were incubated 
overnight at 37 °C at 800 rpm in a Vortemp56 incubator. This plate is referred to as the master 
plate.  
The cavities of a new U-shape 96 well polypropylene plate were filled with 150 µL 2xYT-GA 
media and each well was inoculated with 10 µL of the overnight culture from the 
corresponding well of the master plate. The fresh cultures were incubated for ~1,5 h at 37 °C 
and 800 rpm until an O.D.600 was reached. To each well Hyperphage particles with a MOI of 
20 was added. The infection took place within 30 min at 37 °C. After that the cells were 
incubated another 30 min at 37 °C with shaking (800 rpm in a Vortemp56 incubator). To 
induce phage production a media change had to be performed, therefore the cells were pelleted 
for 10 min in a centrifuge at 3220 xg and the media was discarded. The pellet was resuspended 
in 150 µL 2xYT-AK media and monoclonal phage were produced overnight at 30 °C and 800 
rpm.  
2.2.3.3 Titer determination  
For titer determination after phage production or elution, phage particles were serially diluted 
in PBS. Ten µL of each phage dilution were used to infect 50 µL of E. coli culture at an 
O.D.600 nm of 0,5 (exponential growth phase). After infection for 30 min at 37 °C, E. coli was 
plated on 2xYT-GA agar and incubated at 37 °C overnight. The colonies were counted and 
the titer was calculated.  
2.2.3.4 Panning for antibody selection  
To generate antibodies against various TcdB domains three rounds of panning were performed 
using the naïve human scFv-libraries HAL9 and HAL10 (Kügler et al., 2015). 
For this purpose, a cavity of a 96 well Costar MTP was either first coated with 5 µg of an 
antigen used for library preclearance and then blocked with panning block, or directly blocked. 
5x1010 phage particles, derived from HAL9 and HAL10 were diluted in 150 µL panning block 
transferred to the preclearance well and incubated for one hour.  
In a next step the phage incubated in the actual panning well. Beforehand, this well had been 
coated with 5/2/1 µg (1st /2nd /3rd panning round, respectively) of antigen in 100 µl PBS for 1h 
at RT or overnight at 4 °C and blocked with 2% MPBST.  
Dissertation Viola Fühner   Materials and Methods 
31 
 
After two hours non-bound phage were removed by stringent washing with PBST 
(10 x / 20 x / 30 x, depending on panning round). The remaining phage were eluted by 
proteolytic cleavage using trypsin (150 µL; 10 μg /mL trypsin in PBS;) for 30 min at 37 °C. 
Ten µL of eluted phage were used for titer determination as described in 2.2.3.3. The colonies 
obtained during titer determination can be used to screen single E. coli clones as described in 
2.2.6.2. 
For the next panning round the remaining phage were amplified. For this purpose, they were 
mixed with 150 µL of an E. coli TG1 culture at O.D.600 nm 0.5 and incubated 30 min at 37 °C. 
Cells were pelleted for ten min at 3220 xg, resuspended in 1 mL 2xYT-GA media and culti-
vated in a VorTempTM 56 incubator at 37 °C and 600 rpm until O.D.600 nm 0.5 was reached. 
Twenty MOI M13K07 phage were added for coinfection to enable subsequent phage 
production. After incubation at 37 °C, 30 min w/o shaking and 30 min with shaking, cells were 
pelleted as described above and media was exchanged to 2xYT-AK media. Phage were 
produced during overnight cultivation at 30 °C and 600 rpm. E. coli cells were pelleted by 
centrifugation at 3220xg for 10 min and scFv-phage containing supernatant was collected, 
50 µL were directly used for the next panning round.  
2.2.3.5 Panning for epitope identification 
Preclearance of library from sticky phage 
A cavity of a 96 well Costar MTP was coated with 1 µg of an unrelated scFv-Fc in 100 µL of 
PBS. The antibody solution was discarded and the well was completely blocked with panning 
block (1% BSA, 1% milk powder in PBST). Per each panning at least 1x109 TcdB-fragment 
phage particles were diluted in 150 µL of panning block and incubated in the preclearance 
well.  
Selection of epitope presenting phage 
To isolate TcdB-fragment phage, that present an epitope containing TcdB fragment as a pIII 
fusion protein an adapted panning protocol with double competition and three successive 
peptide-phage - antibody interaction steps was used. For this purpose, three wells were coated 
with 1 µg scFv-hFc of interest. Afterwards the wells were blocked with 2% MPBST. The 
precleared phage were transferred to the first of the three panning wells and 1 µg of the anti 
ErbB4 antibody was added in solution as competitor. Every hour the unbound phage were 
transferred to the consecutive panning well. To prevent the previous wells from drying and to 
diminish sticky phage 1µg of an unrelated antibody in 150 µL PBST was added. When 
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incubation in the third well was completed, weakly bound phage were removed by washing 
with PBST in a Tecan Columbus ELISA washer using the following programs: well one- 10x 
harsh bottom washing; well two- 9x normal washing; well three- 3x normal washing. 
Remaining phage were eluted using 150 µL 10 µg/mL trypsin during an incubation for 30 min 
at 37 °C. Eluted phage were collected and 10 µL were used for titer determination as described 
in 2.2.3.3. 
 
2.2.4 Biochemical methods  
2.2.4.1 Protein A purification of Fc-fusion Proteins  
Recombinantly produced antibodies were purified by affinity purification with the protein A 
MabSelect™ System (GE Healthcare) in a 24 deep well vacuum filtration plate. The column 
material was equilibrated by 3x washing with PBS. Up to 9 mL of cell free production 
supernatant were filled into the wells and allowed to pass the column material by gravity flow. 
After 5 min of incubation vacuum was applied to remove remaining supernatant. For larger 
production scales the loading step was repeated. The protein A matrix was washed three times 
with PBS to remove unbound impurities. Afterwards antibodies were eluted at pH3 in three 
steps. First 500 µL of protein A elution buffer was added to the matrix and incubated for 5 
min, vacuum was applied. The second and third elution were performed with 750 µL elution 
buffer. To neutralize pH, the eluted antibodies were directly mixed with 220 µL of 1 M Tris. 
Afterwards the buffer of the eluate was exchanged to PBS either by use of Zeba™ Desalt Spin 
column or by dialysis. Antibody concentration was determined via UV/VIS spectrometry 
using Nanodrop ND1000. Purified antibodies were stored at -80 °C.  
2.2.4.2 Discontinuous SDS PAGE  
Produced proteins were analyzed by discontinuous SDS-PAGE as described by Laemmli 
(Laemmli, 1970) with a stacking gel to focus the proteins and a separation gel. The 
compositions are given in the following tables (Table 2-19, Table 2-20).  
Table 2-19:composition stacking gel 
Stock solution Volume per gel 
Water 1.0 mL 
30 % (w/v) Acrylamide/Bis 260 µL 
1 M Tris-HCl, pH 6.8 200 µL 
10 % (w/v) SDS 15 µL 
10 % APS (Ammonium persulfate in H2O) 15 µL 
Tetramethylethylendiamin 2 µL 
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Table 2-20: composition separation gel 
Stock solution 
Volume per 12% 
gel 
Water 1.3 mL 
30 % (w/v) Acrylamide/Bis 1.6 mL 
1.5 M Tris-HCl, pH 8.8 1.0 mL 
10 % (w/v) SDS 40 µL 
10 % APS (Ammonium persulfate in H2O) 40 µL 
Tetramethylethylendiamin 2 µL 
 
Laemmli buffer was added to the protein samples and after denaturation for 10 min at 96 °C 
samples were loaded to the gel. The samples were separated at 25mA /gel for 45-55 min. 
2.2.4.3 Coomassie staining of SDS gels  
The polyacrylamide gel was placed in a glass dish, covered with Coomassie staining solution 
and heated shortly in a microwave. Afterwards the gel was incubated on a rocker until the 
staining was complete. The gel was rinsed with water and destained using acetic acid (10 v/v). 
When the protein bands became clearly visible and the background staining was fainted the 
gel was documented. 
2.2.4.4 Silver stain of SDS gels 
The polyacrylamide gel was submerged in fresh fixation solution and incubated for 1 hour at 
room temperature on a rocker. Afterwards, it was dehydrated by three subsequent incubations 
in 50 % (v/v) ethanol of 15 min. The gel was incubated 1 min in 0.13 mg mL-1 Na2S2O3 and 
was washed three times 20 s with water. Next, it was incubated for 20 min in staining solution 
and washed two times 20 s with water. After adding of developer solution protein bands 
became visible within a few min. The gel was washed two times 2 min with water and staining 
was stopped by incubation in stopping solution. The gel was stored in water and documented. 
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2.2.6 Immunological assays  
2.2.6.1 Western blot and immunostaining  
For specific detection of proteins in a sample, or for antibody characterization, western blotting 
with subsequent immunostaining was performed. 
Proteins were transferred from an SDS-Gel to a PVDF membrane by semi dry blotting using 
the Trans-Blot® Turbo™ transfer system (Biorad). The blotting sandwich was built up in the 
blotting cassette according to manufacturer’s instructions. According to the size of the target 
proteins a Bio-Rad optimized protocol was chosen. Large proteins (>150 kDa; TcdB and 
fragments) were blotted for ten min, with constant current of 1.3 A and up to 25 V, smaller 
proteins for 30 min, with up to 1.0 A and constant voltage of 25 V. After blotting the PVDF 
membrane was blocked by incubation in 2 %MPBST for 1h at room temperature on a rocker. 
The blot was submerged in a dilution of primary antibody in 2 % MPBST and incubated at 
least 1 h at room temperature or 4 °C overnight. Afterwards the blot was washed three times 
using PBST and incubated with the AP- conjugated secondary antibody diluted in MPBST for 
45 min at room temperature on a rocker. 
After another washing step (three times with PBST) the blot was developed with NBT BCIP 
(100 µL each in 10 mL of AP substrate buffer) until bands became visible. The membrane was 
thoroughly washed with water and dried between paper towels. 
2.2.6.2 Indirect antigen ELISA for scFv screening 
Supernatants from soluble scFv production in MTP (see 2.2.2.4) were screened for specific 
binding by indirect antigen ELISA. Therefore, each cavity of a Costar 96 well ELISA plate 
was coated with 100 ng antigen in 100 µL PBS, either overnight at 4 °C or 1,5 h at RT. All 
cavities were blocked with MPBST. Afterwards, as well as after each of the following 
incubation steps, plates were washed three times with ddH2O- 0,05% Tween, all antibodies 
were diluted in MPBST. ScFv containing E. coli supernatants were transferred to the assay 
plate in a 1:2 dilution and incubated 1,5 h. After washing anti c-Myc antibody 9E10 was added 
to the wells and incubated 1 h. Bound 9E10 antibody was detected with HRP conjugated anti-
mouse antibody in a 1:40.000 dilution (A0168, Fcγ specific). After final washing ELISA was 
developed with freshly prepared TMB substrate solution for up to 30 min. Colorimetric 
reaction was stopped by addition of an equal volume of stop solution and signals were detected 
in an ELISA reader (signal at 450 nm, reference at 620 nm).  
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2.2.6.3 Indirect antigen ELISA for scFv-Fc characterization  
To determine binding specifity of produced scFv -Fc antibodies as well as to map the binding 
region of the antibodies, indirect antigen ELISAs were performed. For this purpose, each 
cavity of a Costar 96 well ELISA plate was coated with 100 ng antigen in 100 µL PBS, either 
overnight at 4 °C or 1.5 h at RT. All cavities were blocked with MPBST by incubation for 1 h 
at RT. Afterwards, as well as after each of the following incubation steps, plates were washed 
three times with ddH2O- 0,05 % Tween using the BioTek HydroSpeed ELISA washer. 
Generated scFv-Fc were used as primary antibodies, diluted in MPBST and transferred to the 
ELISA plate. After incubation of 1 h and subsequent washing, bound scFv-Fc were detected 
using an HRP-conjugated goat anti-human IgG (Fc specific) antibody (A0170; Sigma-
Aldrich) in a 1:70,000 dilution. The ELISA was developed using TMB substrate and 
colorimetric reaction was stop with H2SO4. Intensity of staining was measured in an ELISA 
reader (signal at 450 nm, reference at 620 nm) and correlates to the amount of scFv-Fc bound 
to the antigen. 
2.2.6.4 Monoclonal phage capture ELISA  
After panning for epitope identification, monoclonal TcdB-fragment-phage from phage 
production in MTP (see 2.2.3.2) were screened for specific binding to selected scFv-Fc 
antibodies. Therefore, the scFv-Fc antibody was diluted in PBS and 100 ng were coated in 
each cavity of a Costar 96 well ELISA plate overnight at 4 °C. The solution was discarded and 
all cavities were completely saturated with 2 % MPBST for one hour. Afterwards, as well as 
after each of the following incubation steps, plates were washed three times with ddH2O- 
0,05 % Tween using the BioTek HydroSpeed ELISA washer.  
Twenty-five µL TcdB-fragment-phage containing E. coli supernatants were transferred to the 
assay plate, mixed with 75 µL MPBST and incubated 1.5 h. Bound Phage were detected using 
HRP conjugated mouse anti-M13 antibody (pVIII specific GE healthcare) in a 1:40,000 
dilution. After 45 min of incubation and washing the ELISA was developed by adding 100 µL 
TMB substrate solution per well. Colorimetric reaction was stopped with an equal volume of 
stop solution and signals were detected (signal at 450 nm, reference at 620 nm).  
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2.2.6.5 Peptide array 
The peptide arrays were purchased from PEPperPRINT GmbH (Heidelberg). The array was 
hydrated at RT with PBST for 15 min on an orbital shaker. Afterwards the array was blocked 
with fluorescent blocking buffer (Rockland). After washing with PBST monoclonal scFv-Fc 
antibodies diluted in staining buffer were incubated on the arrays overnight at 4 °C and 200 
rpm. The array was washed 3 x (few secs) with PBS-T. Anti-Human IgG-Fc Fragment cross-
adsorbed DyLight 680 conjugated antibody (Biomol) was diluted 1:200 in staining buffer and 
incubated on the array (30 min, RT, 200 rpm). The array was washed three times with PBST, 
dipped in 1 mM TrisHCl pH7.4 and air dried. Fluorescence signals at 700 nm was scanned. 
Afterwards the HA-tag control peptides were stained, using Anti-HA Peptide Ready Tag 
Mouse IgG2b (BioXcell) in a 1:5000 dilution in staining buffer as a primary, and Anti-Mouse 
IgG (H+L) DyLight 680 conjugated antibody (Cell Signaling Technology) 1:5000 in staining 
buffer as a secondary antibody. Incubation with both antibodies was 30 min at RT and 200 rpm 
followed by three times washing with PBST. After staining was completed, arrays were dipped 
in 1mM TrisHCl pH7.4, air dried and used for a second scan. 
Analysis of the scans was performed using the software Pep Slide Analyzer. 
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2.2.7 Cell biological methods  
2.2.7.1 Storage of mammalian cells  
For longer time periods mammalian cells were stored in the vapor phase over liquid nitrogen 
in freezing media containing DMSO (% of DMSO depends on the cell line) as 
cryoprotectant.  
2.2.7.2 Thawing of Vero cells  
An aliquot of ~3x10^6 Vero cells was removed from the nitrogen tank and directly placed into 
a water bath, tempered at 37 °C. As soon as the cell suspension was melted it was diluted in 
5 mL prewarmed cultivation media (RPMI 1640 supplemented with 10% (v/v) FCS and 2 mM 
stable L-Glutamine). To remove the DMSO, cells were carefully pelleted at 130 xg for five 
min., supernatant was discarded and cells were transferred to a 75T flask containing 20 mL 
cultivation media already pH equilibrated by incubation at 37 °C in 5% CO2. Cells were 
incubated at 37 °C and 5% CO2 and monitored daily after thawing. 
2.2.7.3 Cultivation and passaging of Vero cells  
Vero cells were passaged two to three times weekly, when cell density was exceeding 90% 
confluency. For this purpose, old media was discarded and cells were washed with PBS to 
remove dead cells and residual media. Trypsin EDTA was added in a way that the cultivation 
area was slightly covered. Cells were incubated at 37 °C for 5-10 min until cell shape changed 
to a spherical shape. Dissociation was stopped by rinsing the full cultivation area with 2,5 
volumes of complete growth media (RPMI 1640 with 10% FBS and 2 mM Glutamine). By 
rinsing and pipetting up and down, cells were detached from the surface and cell aggregates 
were dissociated. 1/20 - 1/5 of cell suspension was seeded into a fresh cultivation vessel filled 
with prewarmed complete growth media. 
2.2.7.4 Freezing of Vero cells  
Vero cells were frozen according to information provided by ATCC®. Vero cells were 
detached from T75 flasks by trypsinization as described in 2.2.7.3. Cell suspension was 
transferred into a 15 mL Falcon tube and an aliquot was used for cell counting in a Neubauer 
chamber. Cells were pelleted at 130 xg for 5 min. The supernatant was discarded and the pellet 
was resuspended in ice cold growth media supplemented with 5% DMSO. The cell density 
was set to > 3x10^6 cells 1.8 mL-1. Cell suspension was aliquoted à 1.8 mL into cryo- screw 
lid tubes. For a controlled freezing process tubes were placed into a pre-chilled (4 °C) freezing 
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container (Mr. Frosty, Nalgene®) filled with isopropanol and transferred to -80 °C. For long 
term storage the cells were moved to a liquid nitrogen tank. 
2.2.7.5 Vero cell intoxication assay with TcdB  
10.000 cells were seeded into each cavity of a 96 well polystyrene plate and cultivated in 
100 µL of complete growth media (RPMI1640 supplemented with 10% (v/v) FBS and 2mM 
L-glutamine) at 37 °C and 5% CO2. The next day TcdB and scFv-Fc antibodies were melted 
on ice, diluted in pre-warmed complete growth media and mixed in a cavity of a 96 well poly-
styrene plate. For all assay plates the following controls were prepared: TcdB only, TcdB + 
isotype control antibody and media only. After incubation of 30 min at RT the cultivation 
media in the Vero cell growth plate was replaced with the TcdB-antibody mixture. Cells were 
monitored for morphological changes. After 4-6 hours, when ~70% of cells in the TcdB – 
isotype control wells were rounded off, pictures of all wells were collected. The percentage of 
round cells in each well was determined by counting, using ImageJ software. 
2.2.7.6 Cultivation of HEK293-6E / Expi293F™ cells 
HEK293-6E and Expi293F™ cells were cultivated in serum free F17 media supplemented 
with 8mM L-glutamine and 0,1 % (w/v) Pluronic-F68 at 37 °C, 5% CO2 and 110 rpm in 
polycarbonate flasks with ventilated caps. Cells were passaged every 2-3 days and seeded to 
a cell density of 0.2 x106 cells mL-1. 
2.2.7.7 Transfection of HEK293-6E/ Expi293F™ cells 
For transient production of scFv-Fcs in mammalian cells PEI mediated transfection of 
HEK293-6E or Expi293F™ cells was performed. 
Per mL of cell culture volume, 1 µg DNA and 5 µg PEI were each diluted in 50 µL F17 media 
(supplemented with 8 mM L-glutamine and 0,1 % (w/v) Pluronic-F68), and then mixed in a 
cavity of a polystyrene plate. After 25 min when the DNA-PEI complex was formed the 
transfection mix was added to HEK293-6E or Expi293F™ cells in exponential growth phase 
(1.5- 1.8 x 106 cells/mL). Cells were cultivated at 37 °C and 5% CO2 in an InforsHT Minitron 
incubator (RPM depended on the cultivation vessel). Two days after transfection cells were 
fed with 1 volume of complete F17 media plus 1/5 volume of TN1 (HEK293-6E cells) or 1 
volume HEK TF (+8 mM L-Glu) plus 1/5 volume HEK FS (Expi293F cells). Production was 
continued for 5 more days, then the cells were pelleted by centrifugation (10 min at 1500 xg) 
and the supernatant was collected to purify the produced scFv-Fc antibodies as described in 
2.2.4.1. 




3.1 TcdB variants for antibody generation and characterization  
 
In this study, a phage display approach was used to generate antibodies against various 
domains and regions of TcdB. For the panning, as well as for subsequent antibody 
characterization and neutralization assays, recombinant TcdB, as well as domains and 
fragments thereof, were used. A schematic representation of the antigen and antigen fragments 
is given in Figure 3-1. 
 
The antigens were produced with a C-terminal 6 x His-tag in a B. megaterium expression 
system, and purified via Ni2+-affinity chromatography, except of TcdBCROPs, which was 
produced as GST-fusion protein in E. coli and purified via Glutathione-sepharose 
chromatography. TcdBCROPs was cleaved from the GST-tag by thrombin cleavage. 
The aa sequence of the TcdB fragments used corresponds to C. difficile strain VPI10463, a C. 
difficile reference strain. TcdBGTD was produced as a glucosyltransferase-deficient mutant 
(D286/288N) for higher yields and purity of the protein.  
All TcdB variants used were kindly provided by Ralf Gerhard, Sebastian Goy and Helma 
Tagte (Hannover Medical School, Institute for Toxicology). 
  
Figure 3-1: Schematic representation of TcdB Fragments 
TcdB fragments used in this study. All Fragments derived from TcdB of C. difficile strain VPI10463.      
TcdBFL: wild type (wt) TcdB; TcdB1-1852: wt TcdB missing the CROP domain; TcdB1-1128: N-terminal 1128 
aa of wt TcdB; TcdBGTD: enzymatically inactive mutant (D286/288N) of TcdB glucosyltransferase domain; 
TcdBCROPs combined repetitive oligopeptides, missing the first short repeat 
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3.2 Antibody generation 
3.2.1 Panning and sequence analysis 
To generate antibodies against the various domains of Clostridioides difficile Toxin B (TcdB), 
a phage display approach was used. Phage display was performed using the two naïve human 
scFv-libraries HAL9 and HAL10 (Kügler et al., 2015).  
To gain a broader antibody diversity and to cover a broader range of epitopes, a total of six 
pannings was performed on either TcdB1-1852, TcdBCROPs or the full-length toxin (TcdBFL). An 
overview over the panning strategies and the success of the pannings is given in Table 3-1. 
Table 3-1 Panning strategies and outcome 
Panning TcdB 
Fragment 






Unique characterized as 
Fc-Fusion 
ViF087 TcdB1-1852 RT TcdB1-1128 92 19 11 10 
ViF088 TcdB1-1852 RT no 92 13 3 3 
ViF090 TcdB1-1852 37 TcdB1-1128 92 17 2 2 
ViF091 TcdB1-1852 37 no 92 11 1 1 
ViF137 TcdBCROPs RT no 92 24 12 8 
SH1429* TcdBFL RT no 92 12 7 7 
Σ human antibodies 552 96 36 31 
*Panning was performed by Saskia Helmsing 
 
For two pannings on TcdB1-1852, a negative preselection on the N-terminal fraction of TcdB 
(TcdB1-1128) was performed to direct the selection pressure towards antibodies that bind within 
the translocation domain (TLD) more exactly, between aa 1128 and aa 1852. 
Since the toxins conformation might be temperature dependent, the panning on TcdB1-1852 was 
performed at room temperature and at 37 °C. The pannings on TcdBCROPs or TcdBFL were only 
performed at room temperature, since panning at 37 °C seemed to decrease antibody diversity, 
as only two and one unique clones could be generated in the pannings at 37 °C on TcdB1-1852 
(ViF090 and ViF091). 
For each panning three rounds of antibody enrichment were performed. Afterwards a total of 
552 clones was screened for production of TcdB specific scFv in an antigen ELISA. As antigen 
in the ELISA the TcdB variant used in the respective panning was immobilized in MTP plates. 
As an example, the result of the screening ELISA after panning on TcdB1-1852 at room 
temperature with negative selection on TcdB1-1128 (panning ViF087) is given in Figure 3-2. 





On basis of the signal intensity and the signal to noise ratio in the screening ELISA, a total of 
96 antibody clones were further analyzed. Sequencing with subsequent V-gene analysis and 
CDR comparison using the VBASE2 tool (Mollova et al., 2010), revealed the isolation of 36 
unique scFvs /monoclonal antibodies (mAbs) (Table 3-2). 
The distribution of the V genes used, as well as the ratio of lambda and kappa antibodies was 
determined: Of the 36 antibodies 15 (41 %) are IGHV1, 18 (50 %) IGHV3, two (5,5 %) 
IGHV5 and one IGHV6. No IGHV2, IGHV4 or IGHV7 antibodies were isolated. Even though 
the lambda- and kappa antibody libraries HAL9 and HAL10 were used in equal amounts in a 
pooled approach, the majority (29) of the isolated antibodies contain a lambda light chain (9x 
IGLV1, 10x IGLV2, 8x IGLV3, 2x IGLV6) and only 7 antibodies (18,9 %) a kappa light chain 
(2x IGKV1, 5x IGKV3).  
  
Figure 3-2: Screening ELISA  
Exemplary shown for the screening after panning on TcdB1-1852 with negative selection on TcdB1-1128. Ninety-two 
clones were screened production of scFv binding to TcdB1-1852. BSA was used as a negative control antigen 
to prove specificity of selected antibodies. As negative control to determine assay background cultivation media 
was used. The positive control was an anti-lysozyme antibody Dm321-F11 on 100 ng coated lysozyme. 




Table 3-2 Germline distribution of selected scFvs 
# mAb name V VH D VH J VH V VL J VL 
1 ViF087_A10 IGHV1-18*01 IGHD3-3*01 IGHJ4*02 IGLV1-44*01 IGLJ3*02 
2 ViF087_B1 IGHV3-30*04 IGHD3-10*01inv IGHJ6*02 IGLV1-47*01 IGLJ3*02 
3 ViF087_B10 IGHV1-46*03 not found IGHJ6*02 IGKV3-20*01 IGKJ4*01 
4 ViF087_E1 IGHV1-69*01 IGHD2-2*01 IGHJ4*02 IGKV3-15*01 IGKJ1*01 
5 ViF087_E7 IGHV1-18*01 IGHD1-26*01 IGHJ3*02 IGKV1-12*02 IGKJ4*01 
6 ViF087_F1 IGHV3-33*01 IGHD4-17*01 IGHJ2*01 IGLV3-19*01 IGLJ3*01 
7 ViF087_F3 IGHV1-3*01 IGHD5-12*01 IGHJ5*02 IGLV2-18*02 IGLJ3*02 
8 ViF087_G10 IGHV1-69*01 IGHD3-22*01 IGHJ5*02 IGLV1-47*01 IGLJ3*02 
9 ViF087_G11 IGHV3-30*01 IGHD4-17*01 IGHJ4*02 IGLV3-19*01 IGLJ3*01 
10 ViF087_H5 IGHV1-46*03 IGHD4-17*01 IGHJ4*02 IGLV2-14*01 IGLJ3*02 
11 ViF088_C5 IGHV3-13*01 IGHD3-16*01 IGHJ4*02 IGLV6-57*01 IGLJ3*01 
12 ViF088_E10 IGHV3-30*18 IGHD6-13*01inv IGHJ6*03 IGLV3-19*01 IGLJ3*02 
13 ViF088_H10 IGHV3-33*01 IGHD3-10*01 IGHJ3*02 IGLV1-51*01 IGLJ3*02 
14 ViF090_A6 IGHV1-69*01 IGHD2-15*01 IGHJ4*02 IGLV6-57*01 IGLJ3*02 
15 ViF090_G5 IGHV1-3*01 IGHD5-12*01 IGHJ5*02 IGLV2-14*01 IGLJ3*01 
16 ViF091_B10 IGHV1-69*06 IGHD2-21*01 IGHJ5*02 IGLV1-44*01 IGLJ3*02 
17 ViF137_A3 IGHV3-23*04 IGHD6-19*01 IGHJ3*02 IGKV3-20*01 IGKJ4*01 
18 ViF137_A6 IGHV3-7*01 IGHD6-13*01 IGHJ4*02 IGLV3-21*02 IGLJ3*01 
19 ViF137_A9 IGHV5-51*01 IGHD1-14*01 IGHJ3*02 IGLV2-8*01 IGLJ3*02 
20 ViF137_C1 IGHV3-23*04 IGHD5-5*01 IGHJ6*02 IGLV2-8*01 IGLJ3*01 
21 ViF137_C2 IGHV3-23*01 IGHD5-18*01 IGHJ4*02 IGLV1-47*01 IGLJ3*02 
22 ViF137_C3 IGHV1-69*01 IGHD6-13*01 IGHJ5*02 IGLV2-8*01 IGLJ3*01 
23 ViF137_E4 IGHV3-21*01 IGHD6-19*01 IGHJ6*02 IGLV2-11*01 IGLJ3*02 
24 ViF137_E7 IGHV5-51*01 IGHD1-1*01 IGHJ3*02 IGLV2-14*01 IGLJ3*02 
25 SH1429_B1 IGHV1-3*01 IGHD5-12*01 IGHJ5*02 IGLV2-14*04 IGLJ1*01 
26 SH1429_B10 IGHV3 IGHD2-8*02inv IGHJ3*02 IGKV3-20*01 IGKJ2*01 
27 SH1429_C10 IGHV3 IGHD2-15*01 IGHJ6*02 IGLV2-8*01 IGLJ3*02 
28 SH1429_D6 IGHV6 IGHD2-2*03inv IGHJ3*02 IGLV3-19*01 IGLJ1*01 
29 SH1429_G1 IGHV3 IGHD2-2*02inv IGHJ3*02 IGKV3-20*01 IGKJ4*01 
30 SH1429_G6 IGHV1-18*01 IGHD3-3*01 IGHJ4*02 IGLV1-40*01 IGLJ3*02 
31 SH1429_H7 IGHV3 IGHD6-19*01 IGHJ4*02 IGLV1-47*01 IGLJ3*01 
32 ViF087_C12 IGHV3-48*03 IGHD3-3*01 IGHJ3*02 IGLV3-19*01 IGLJ3*02 
33 ViF137_A1 IGHV1-2*02 IGHD4-17*01 IGHJ5*02 IGLV1-51*01 IGLJ3*01 
34 ViF137_A5 IGHV3-30*04 IGHD5-12*01 IGHJ4*02 IGLV3-19*01 IGLJ3*01 
35 ViF137_D1 IGHV1-2*02 IGHD6-13*01 IGHJ4*02 IGKV1-5*01 IGKJ1*01 
36 ViF137_D4 IGHV3-23*04 IGHD4-23*01 IGHJ4*02 IGLV3-19*01 IGLJ3*01 
Antibodies not included in further characterization 
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Compared to the small scFv format that is well suitable for phage display and production in 
E. coli, the scFv-Fc format has some advantages for antibody characterization. First it has a 
higher apparent affinity, second it can be easily purified by Protein A affinity chromatography 
from mammalian cell culture production supernatant. To enable the production of monoclonal 
antibodies in HEK293-6E cells in an scFv-Fc format with a human IgG1 Fc part, the scFv 
genes were cloned into the mammalian expression vector pCSE2.6-hIgG1-Fc-XP. The success 
of cloning was verified by colony PCR and sanger sequencing (data not shown).  
The plasmid DNA was transfected into HEK293-6E cells or Expi293F™ cells for transient 
production for a time period of seven days in suspension culture. The antibodies were purified 
from the culture supernatant by protein A affinity chromatography. 
The purity and integrity of the scFv-Fc preparations was controlled by reducing SDS-PAGE 
with subsequent Coomassie staining (representative example given in Figure 3-3Figure 3-3: 
Coomassie stained SDS PAGE of purified scFv-Fc antibodies). As expected, all antibodies 
had an apparent molecular weight of ~ 60 kDa. They run in the SDS-PAGE as multiple bands, 
which is due to glycosylation. Since there were no visible impurities or breakdown products 
of the scFv-Fcs, the degree of purity of the antibody preparations was above 95 %.  
 
The produced scFv-Fc antibodies were used in further experiments to characterize the 
antibody antigen interaction and functional cell-based assays to test antigen neutralization. 
  
Figure 3-3: Coomassie stained SDS PAGE of purified scFv-Fc antibodies 
Antibodies from panning on TcdBFL (Panning SH1429) were produced in HEK293-6E cells in 5 mL scale 
as scFv-hIgG1-Fc. Antibodies were purified from the supernatant by protein A affinity chromatography. 
0,5 µg of the respective antibody was applied to a 12% polyacrylamide gel under reducing conditions. 
After electrophoresis proteins were stained using Coomassie blue staining solution. 
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3.2.2 Validation of antigen binding and domain mapping 
Thirty-one of the 36 generated mAbs were successfully produced in scFv-Fc format and 
further analyzed by titration ELISA. This ELISA was designed to verify that format change 
from scFv to the bivalent scFv-Fc did not impair antigen recognition, second, to analyze 
TcdBFL binding of antibodies that were generated on TcdB fragments, third, to validate 
antibody specificity and fourth, to determine the binding domains or regions of the respective 
mAbs. Therefore, the binding to four different TcdB variants (TcdBFL, TcdB1-1852, TcdBGTD 
and TcdBCROPs) as immobilized antigens was addressed in this ELISA (Figure 3-4, Table 3-5).  
In this ELISA setup, all mAbs bound to their respective panning TcdB variant in a 
concentration dependent manner: The mAbs derived from the panning on TcdB1-1852 (ViF087, 
ViF088, ViF090 and ViF091) also bound TcdB1-1852 after format change. For the antibodies 
generated on TcdBCROPs (ViF137), the binding to the CROPs domain was validated and the 
antibodies originating from the panning on TcdBFL still bound to full-length toxin. However, 
the antibodiesViF137_C3 (Figure 3-4 H) and SH1429_B10 (Figure 3-4 I) showed a very weak 
binding in ELISA.  
The antibodies were also tested on TcdBFL as antigen, since epitopes that might be accessible 
in TcdB fragments might be shielded by parts of the protein in TcdBFL. Also, the overall 
folding of different TcdB variants might be different. Interestingly, almost no binding to 
TcdBFL was detected for some mAbs [ViF087_G11, ViF087_H5 (Figure 3-4 A), ViF088_C5, 
ViF088_E10 and ViF137_C2 (Figure 3-4 E)] despite of binding to the panning antigen. For 
further antibodies [ViF087_A10, ViF087_B1, ViF087_B10, ViF087_F1 (Figure 3-4 A), 
ViF091_B10, ViF137A9 and ViF137_C1 (Figure 3-4 E)] the binding to TcdBFL was notably 
reduced (≤50% signal intensity at highest concentration) compared to the respective panning 
TcdB variant. 
To validate domain specificity, the antibodies derived from pannings on the N-terminal 
fraction of TcdB were tested for binding on the C-terminal CROPs domain and vice versa. As 
expected, there was no binding to TcdB1-1852 or TcdBGTD of mAbs that were generated by 
panning against TcdBCROPs [mAbs ViF137 (Figure 3-4 F, G)] and no binding to TcdBCROPs of 
mAbs that were generated by panning against TcdB1-1852 [mAbs ViF087, ViF088, ViF090 and 
ViF091_B10 (Figure 3-4 D, H)] proving domain specificity of the mAbs generated in this 
study. 








Figure 3-4: Titration ELISA on TcdB variants: 
31 mAbs were tested for binding on 100 ng immobilized TcdB variants. Bound scFv-Fcs were detected using a 
HRP conjugated anti- human Fcγ antibody (Sigma Aldrich, A0170, 1: 70,000 in MPBST). A, E, I: Titration on 
TcdBFL; B, F, J: Titration on TcdB1-1852; C, G, K: TcdBGTD was used as antigen; D, H, L: Titration on 
TcdBCROPs 
Of the 31 mAbs tested in this assay, 14 bound to TcdBCROPs, among them all antibodies 
derived from the panning against TcdBCROPs [mAbs ViF137 (Figure 3-4 H)], as well as the 
majority of the antibodies derived from the panning against TcdBFL [SH1429_B10, 
SH1429_C10, SH1429_D6, SH1429_G1, SH1429_G6 (only very weak) and SH1429_H7 
(Figure 3-4 L)]. 
Four mAbs [ViF087_E1, ViF088_C5, ViF088_H10 and ViF090_A6 (Figure 3-4 C, G)] bound 
to TcdBGTD in a concentration dependent manner indicating an epitope within the GTD domain 
of TcdB. The remaining 13 antibodies bound to immobilized TcdB1-1852, but not to TcdBGTD. 
Therefore, it is likely that these antibodies bind to epitopes between aa 543 and aa 1852, but 
due to possible differences in protein folding between the different TcdB variants, and the two 
amino acids exchanged in TcdBGTD compared to wt sequence used in TcdB1-1852, a lack of 
TcdBGTD binding in this experiment is not sufficient to exclude an epitope within this domain. 
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3.3 In vitro neutralization 
In this study 31 unique antibodies against TcdB were generated and binding validated by anti-
gen ELISA. But mere antigen binding is not an indicator for TcdB neutralization. However, 
for possible further clinical development of the antibodies potent TcdB neutralization is 
required. Additionally, neutralizing and to some extend also non-neutralizing antibodies can 
be of great value to gain deeper understanding of the toxin’s mode of action, especially when 
the respective epitopes or binding regions of the antibodies are known. 
To address the neutralization capacity of the antibodies, they were tested for in vitro 
neutralization of TcdB. Therefore, a cell-based assay with Vero cells was used. This assay is 
based on the cell rounding induced by TcdB: Upon cellular uptake of TcdB and release of the 
glucosyltransferase domain to the cytosol, the glucosyltransferase domain glucosylates small 
Rho GTPases which impairs several cell-signaling pathways and consequently leads to a 
breakdown of the actin cytoskeleton. This effect includes morphological changes like the 
formation of retraction fibers and finally the typical TcdB induced-cell rounding (see Figure 
3-5). The cell rounding was also used as read out for this assay.  
Neutralization efficacy of an antibody was analyzed by comparing percentage of round cells 




Figure 3-5: TcdB induced cell rounding of Vero cells 
Left panel: Vero cells cultivated with supplemented RPMI medium. Right panel: Vero cell treated with 0,1 pM 
TcdB  
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3.3.1 TcdB induces concentration dependent cell rounding of Vero cells 
In a first test, the optimal working concentration of TcdBFL for this assay had to be determined. 
Therefore, a serial dilution of TcdB was prepared in culture media and applied to Vero cells. 
After 5 h of intoxication pictures of the cells were collected and the percentage of round cells 
was determined. Cell rounding was correlating with TcdBFL concentration (see Figure 3-6). 
 
For following neutralization experiments a TcdBFL concentration of 0.1 pM (a concentration 
corresponding to ~ 80% cell rounding) was used. To be able to also notice slight neutralization 
effects mediated by the antibodies a concentration of TcdB that is beyond saturation was 
chosen. 
Figure 3-6: In vitro intoxication of Vero cells using a serial dilution of TcdBFL 
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3.3.2  Antibody mediated inhibition of TcdB induced cell rounding  
To test if the antibodies generated in this study confer in vitro neutralization of TcdB, 0.1 pM 
of the active full-length toxin was coincubated with 100 nM mAb in cultivation media. After 
preincubation to give time to establish an antibi antigen binding the mixture was transferred 
to Vero cells. When cell rounding in control wells (TcdB w/o antibody) was ~80% pictures of 
the cells were collected. To determine neutralization efficacy, the percentage of round cells 
was determined and normalized to the percentage of round cells in the control wells (Vero 
cells w/o TcdBFL and Vero cells with TcdBFL w/o mAb). 
In a first screening for neutralization including all 31 antibodies that were further characterized 
in this study, all mAbs reduced the percentage of round cells after TcdB treatment to some 
extent, thus all antibodies had at least slight neutralizing effects. However, significant 
neutralization was achieved with 12 out of 31 mAbs (p <0.0001) (Figure 3-7).  
For five antibodies (ViF087_B1, ViF087_E7, ViF090_G5, ViF137_E4 and SH1429_H7) 
preincubation of TcdB with either one of them resulted in more than 50 % neutralization. Best 
in vitro neutralization of TcdB was achieved using ViF087_A10, ViF087_F3 and SH1429_B1 
(>75 % reduction of cell rounding).  
  
Figure 3-7: Screening for in vitro TcdB neutralization:  
Initial screening for neutralization using all 31 mAbs in a 10,000-fold molar excess. Bars represent technical 
triplicates with SD as error bars. A one-way ANOVA test was performed for each antibody against the isotype 
control TM43_E10 (Kügler et al., 2015). *: p <0.0001 
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To validate the efficient TcdBFL neutralization of ViF087_A10 and SH1429_B1 and to be able 
to estimate IC50 values of these mAbs in this assay, a serial dilution was performed (Figure 
3-8). ViF087_F3 was not included since it contains the same heavy chain as SH1429_B1 
which suggests a neutralization via the same epitope. Furthermore, size exclusion 
chromatography revealed partial aggregation of ViF087_F3, which is not the case for 
SH1429_B1 (Supplementary Figure 7-1).  
The dilution series confirmed the results of the neutralization screening. At the starting 
concentration of 100 nM ViF087_A10 and SH1429_B1 nearly completely inhibited the cell 
rounding induced by TcdBFL intoxication (Figure 3-8). However, the dilution series revealed 
that SH1429_B1 is roughly ten times more potent than ViF087_A10, since 0.1 nM 
SH1429_B1 were sufficient to reduce cell rounding by ~50% whereas 1 nM of ViF087_A10 
was needed to achieve a comparable effect.  
In a next assay a combination of ViF087_A10 and SH1429_B1 was used to neutralize TcdBFL 
in an in vitro assay, but neutralization achieved with this combination was not stronger as for 
SH1429_B1 alone (data not shown). 
  
Figure 3-8:Validation of in vitro TcdB neutralization for ViF087_A10 and 
SH1429_B1 
IC50 values of ViF087_A10 and SH1429_B1 were estimated with serial 
antibody dilutions. 
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3.3.3 Inhibition of TcdB induced cell rounding using antibody combinations  
Unlike Bezlotoxumab, the human anti- TcdB antibody already approved by the FDA for 
therapy of recurrent CDI (Navalkele and Chopra, 2018), the two most potent neutralizing 
antibodies generated in this study (ViF087_A10 and SH1429_B1) bind to epitopes within 
TcdB1-1852 (Figure 3-4 B, J). Bezlotoxumab binds to two epitopes within the CROPs which are 
involved in cell binding via carbohydrate structures (Orth et al., 2014) and or inhibition of 
binding to CSPG4 (Gupta et al., 2017), proving that neutralization via this repetitive domain 
is feasible. However, three cellular receptors of TcdB are described that bind to TcdBTLD, with 
members of the frizzled family, which bind to TcdB1285-1804 (aa 1285-1804 contain the FZD 
binding site, with amino acids between position 1430 and 1600 directly involved in protein- 
protein interaction) with an affinitiy of 13 nM (Chen et al., 2018; Gupta et al., 2017; LaFrance 
et al., 2015; Tao et al., 2016; Yuan et al., 2015). Hence, it might be possible that the anti-
TcdBCROPs antibodies generated in this study reduce CROPs mediated binding of TcdB to the 
cell surface, but that TcdB induced cell rounding is not reduced, because of the numerous 
compensation mechanisms, mediated by the additional cell surface receptors. In this case a 
combination of the mAbs directed against TcdBCROPs with mAbs that bind to the N-terminal 
domains could lead to improved neutralization and synergistic effect. To test this hypothesis, 
combinations of either ViF087_A10 or SH1429_B1 with mAbs directed against TcdBCROPs 
were tested in an in vitro TcdB neutralization assay. Therefore 0,1 pM of TcdB was 
preincubated with 1 nM ViF087_A10 or 0,1 nM SH1429_B1 [the concentration needed for 
~50% TcdB neutralization as determined by titration (Figure 3-8)] and 100 nM of either of the 
14 anti- TcdBCROPs mAbs for 30 min at room temperature and then transferred to Vero cells. 
TcdB neutralization for each antibody combination was compared to neutralization achieved 
with ViF087_A10, or SH1429_B1 alone in the same assay, as well as with neutralization 
achieved in the first screening.  
Neutralization mediated by 1 nM ViF087_A10 in this assay was 41%. Addition of a second 
mAb directed against TcdBCROPs in a concentration of 100 nM increased neutralization. The 
highest total neutralization for ViF087_A10 was in combination with ViF137_E4 (73%), 
SH1429_C10 (70%) and SH1429_H7 (66%) (Figure 3-9 A).  
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For SH1429_B1, 0,1 nM mAb reduced cell rounding by 49%. As for ViF087_A10, addition 
of 100 nM of an anti- TcdBCROPs mAb increased neutralization and best neutralizing with 
SH1429_B1 was achieved in combination with the same TcdBCROPs binders as for 
ViF087_A10, namely ViF137_E4 (79%), SH1429_C10 (78,9%) and SH1429_H7 (83,6%) 
(Figure 3-9 B).  
 
Figure 3-9: In vitro TcdB neutralization using antibody combinations 
In vitro neutralization assay of 0,1pM TcdB using antibody combinations. TcdB and either 1 nM of ViF087_A10 
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Remarkably, the anti- TcdBCROPs mAbs leading to the highest increase of neutralization with 
either ViF087_A10 or SH1429_B1 in this assay were same mAbs that already showed best 
neutralization among TcdBCROPs binders in the initial screening as single antibodies 
(ViF137_E4 53%, SH1429_C10 48%, SH1429_H7 56%). Therefore, the increase of 
neutralization in this combinatory assay was based on additive- rather than synergistic effects.  
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3.4 Epitope mapping  
For future rational development of toxin neutralizing antibodies as therapeutics for CDAD, or 
TcdB fragments as vaccines, more information about potential neutralizing epitopes is re-
quired. To identify the epitopes of ViF087_A10 and SH1429_B1 that elicit neutralization, as 
well as to gain more information about the binding sites of the remaining antibodies, three 
different assays were performed, that, taken together, provide deep information about the 
antibody-antigen interaction and the nature and location of the antibodies’ epitopes. 
 
3.4.1 Epitope characterization by test of antibodies in immunoblots 
The first assay addressed the question what kind of epitopes the antibodies bind. In general, 
epitopes can be classified as linear or conformational epitopes. Linear epitopes consist of a 
continuous stretch of aa on the primary structure, therefore binding of the antibody to a linear 
epitope does not depend on protein folding. If the antibody binding to its epitope requires 
protein folding the epitope is designated conformational. Conformational epitopes can be 
either continuous or discontinuous, which refers to the positioning of the contributing amino 
acids on the primary structure. Upon protein folding, amino acids that are located far apart on 
the primary structure can come into close proximity and thus build discontinuous epitopes.  
Upon heating in SDS and ß-Mercaptoethanol containing buffer, the proteins are denatured and 
therefore discontinuous epitopes as well as, at least partially, continuous conformational 
epitopes are destroyed. Hence, testing the antibody binding to denatured protein transferred to 
a PVDF membrane by western blotting can give valuable information about the nature of an 
antibody’s epitope. 
Hence, 5 µg of the TcdB variants were analyzed under denaturing and reducing conditions in 
SDS-PAGE followed by western blotting and immunostaining. An exemplary result of an 
immunostaining is given in Figure 3-10 and the overall results are summarized in Table 3-5. 
Of the seventeen antibodies binding to TcdB1-1852 only two ViF088_H10 and ViF090_A6 
bound to denatured TcdB variants (see Figure 3-10). For eight mAbs mixed results were 
obtained, either the binding was very weak, or not all TcdB variants tested were bound. For 
another seven antibodies against TcdB1-1852 there was no binding to denatured TcdB at all.  
Of the 14 antibodies binding to TcdBCROPs only one did not bind to denatured TcdB whereas 
the remaining 13 did (data not shown). 





Whilst most antibodies directed against the N-terminal fraction of TcdB seem to bind 
conformational epitopes, the antibodies against the C-terminal CROPs most likely bind to 
linear epitopes.  
  
Figure 3-10: Immunoblot staining of TcdBFL 
SDS and ß Mercaptoethanol treated TcdBFL was applied to an SDS gel and after electrophoresis transferred 
to a PVDF membrane. Blotted protein was detected using various mAbs from this study as primary- and an 
AP conjugated anti-human Fc-antibody as secondary antibody. The immunoblot was developed using 
NBT/BCIP substrate. From the panel of mAbs shown here, ViF088_H10 and ViF090_A6 bound strongly to 
denatured TcdBFL. There might also be very slight binding of ViF088_C5, but this is regarded as an unclear 
result.  
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3.4.2 Epitope mapping by peptide array  
As a first approach for epitope mapping, a peptide array was used, which enables parallelized 
epitope screening for a larger number of antibodies. Disadvantage of this method is that 
discontinuous epitopes cannot be mapped and also conformational epitopes can be 
problematic, because of the limited size of the peptides. For this study 15 mer peptides were 
used which at least allow the formation of α-helical structures. Also, due to very high local 
concentraions of the spotted peptides, the sensitivity of this assay might be higher than the 
immunoblot analysis. 
The arrays were spotted with peptides of TcdB with an offset of two amino acids (example 
given in Table 3-3). The experiment was performed in collaboration with Jasmin Heidepriem 
and data evaluation with Dr. Felix Loeffler (Max Planck Institute of Colloids and Interfaces). 
Table 3-3: Layout of the peptide array 
Amino acids of TcdB Row column Peptide Sequence  
414- 428 8 14 LNPAISEDNDFNTTT------ 
416- 430 8 15 --PAISEDNDFNTTTNT---- 
418- 432 8 16 ----ISEDNDFNTTTNTFI-- 
420- 434 8 17 ------EDNDFNTTTNTFIDS 
 
All antibodies were tested at a concentration of 1 µg/mL. For a significant number of 
antibodies signal intensity was very low with this concentration or there were no signals 
detectable at all. In these cases, incubation with primary and secondary antibody was repeated 
at a concentration of the primary antibody of 100 µg/mL. Unfortunately, this approach was 
not successful for most antibodies or results were difficult to interpret. One such example is 
mAb ViF087_B10. The 15 peptides that showed strongest binding include four neighboring 
peptides starting at aa positions 288, 290, 292 and 294, so this region was highly 
overrepresented in the top hits. Nevertheless, this antibody seemed to have a broader cross-
specificity as the remaining 11 peptides originated from different regions of the toxin and 
didn`t have common features (see Supplementary Table 7-1). 
Nevertheless, the two neutralizing antibodies ViF087_A10 and SH1429_B1 both specifically 
bound to five 15 mer peptides starting between aa 414 and 422. ViF087_A10 also interacted 
with two further peptides starting at aa 402 and 404 (Figure 3-11). 
MAb ViF087_E1 strongly, but not exclusively, bound to a peptide that spans aa 522-537 
(Supplementary Table 7-2). 
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Two antibodies (ViF137_A9 and ViF137_E7) reacted with three and four clusters of peptides 
within the CROP domain (aa 1858-1869, 2084-2095, 2216-2227 and aa 1860-1867, 2084-
2093, 2218-2225, 2236-2249 respectively) (Figure 3-11). These clusters contain a common 
motif which probably reassembles the key amino acids necessary for antibody-antigen 
interaction [KYYF† († =D or N) and *KYYF† (*=I, S or D; † =D or N), respectively] 
(Supplementary Table 7-2).  
 
Further antibodies that, according to the ELISA, were directed against the CROPs, namely 
ViF137_A3, ViF137_A6, ViF137_C3, SH1429_C10, SH1429_D6 and SH1429_G1 reacted 
with peptides derived from the CROPs. But the result of the peptide array was difficult to 
interpret, since they did not exclusively bind to only one cluster of neighboring peptides but 
showed a higher degree of cross-specificity or tolerance of aa substitutions, therefore epitope 
identification only by peptide array was not feasible for these antibodies.  
  
Figure 3-11: Exemplary results of the peptide array: 
Result of the peptide array exemplary shown for four of the 31 antibodies tested. ViF087_A10 and SH1429_B1 
react with a cluster of peptides within the GTD domain. ViF137_A9 and ViF137_E7 bind to three clusters of 
peptides within the CROPs 
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3.4.3 Epitope mapping by phage display 
To confirm the epitopes regions found by peptide array and to identify further epitopes or at 
least binding regions of the remaining antibodies a second, independent approach was chosen 
for epitope mapping, namely TcdB-fragment phage-display. This approach has the advantage 
that also larger TcdB-fragments (>100 aa) can be displayed on the phage, therefore the chance 
to also map conformational or even discontinuous epitopes is higher.  
To generate a TcdB-fragment phage display library, the tcdB-gene was amplified from 
genomic DNA of C. difficile strain 630 and the amplicon was fragmented. As analyzed by 
agarose gel electrophoresis, sonication led to DNA fragments of ~ 100- 400 bp in size (Figure 
3-12). 
 
After blunt end polishing, DNA fragments were ligated into pHORF3 vector that was 
subsequently used for transformation of electrocompetent E. coli (strain TOP10F’). 
Electroporation led to transformation of 1,9 x 107 independent clones.  
Due to the undirected blunt end cloning and the random fragmentation of the amplified tcdB 
gene, in theory only 1 out of 18 clones obtained by electroporation would carry a tcdB-
fragment- gIII fusion that leads to expression of a functional fusion protein [50% right 
orientation, 33% thereof correct reading frame of the insert, 33% thereof right insert length 
(3n+1) to get the signal sequence and gIII in the same reading frame].   
Figure 3-12: Analysis of DNA fragmentation after sonication 
An aliquot of fragmented DNA was applied to a 2% Agarose gel. Fragmentation using the Bioruptor 
sonicator system led to tcdB fragments ranging from ~100 -400 bp in length. 
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Hence, the tcdB-gene fragment library was packaged with Hyperphage (M13K07ΔgIII), 
missing a functional gIII. Consequently, pHORF3 plasmids with a tcdB insert of 3n+1 
nucleotides and without stop codons were the sole source of functional gIII, which led to an 
enrichment of correct open reading frames (Table 3-4).  
After purification of TcdB-fragment phage, a test infection of an E. coli XL1 blue MRF’ 
culture at an O.D.600 nm of 0,5 was performed. Infected E. coli clones were thinned out and 92 
randomly picked single clones were sequenced to analyze insert size, ORF enrichment and 
TcdB coverage of the library after packaging into phage. A summary of the library 
characterization is given in Table 3-4. The library characterization was performed in 
collaboration with Philip Heine. 
 
Table 3-4: Characterization of TcdB-fragment library 
Library size (independent clones, 
before packaging) 
1,9 x 10^7 
In frame insert rate after packaging 65% 
Mean insert length 39 aa 
data of packaged library before 
panning 
Shortest TcdB fragment found 13 aa 
Longest TcdB fragment found 73 aa 
 
Sequencing revealed, that ORF enrichment was successful: sixty out of the 92 clones (65%) 
carried correct inserts within the pHORF3 plasmids, allowing expression of functional TcdB-
fragment-pIII fusions. Also the TcdB-protein coverage was addressed, therefore the translated 
DNA sequences of all 60 clones carrying functional TcdB-fragment pIII fusions were aligned 
to the TcdB aa sequence (see Supplementary Figure 7-2). A complete coverage was not 
achieved with this limited number of clones, but fragment distribution was rather even.  
The TcdB-fragment library was used for pannings on immobilized mAbs and/or pannings in 
solution. The pannings were performed together with Philip Heine. For the pannings in 
solution, the TcdB-fragment phage bound to the respective mAb were separated from unbound 
phage by immunoprecipitation using protein A coupled magnetic beads.  
The isolated phage were used to infect E. coli in logarithmic growth phase. Successfully 
infected E. coli clones were selected with the help of an ampicillin resistance mediated by the 
pHORF3 plasmid. E. coli clones, carrying tcdb-gene fragments coding for the potential epitope 
region were identified by monoclonal phage ELISA on immobilized mAbs.   
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For 18 out of 31 mAbs the screening ELISA resulted in the identification of monoclonal, 
TcdB- fragment presenting phage that specifically bound to the corresponding anti- TcdB-
antibody but not to an irrelevant control antibody (exemplary shown for SH1429_C10 in 
Figure 3-13).  
 
Based on the signal to noise ratio clones were selected for sequencing. Also clones yielding 
lower ELISA signals were included, since affinity of the antibodies to shorter TcdB-fragments 
(which might provide higher epitope resolution) might be comparably lower, thus leading to 
decreased binding and consequently lower signal intensity in ELISA. 
The obtained sequences were translated into aa sequences and aligned to the TcdB sequence. 
For each mAb, the stretch of amino acids that was covered by all sequenced clones (excluding 
clear outliers) that carried correct inserts in the pHORF3 vector, is referred to as the minimal 
epitope region (MER) (Table 3-5). This region encompasses the core amino acids for antigen- 
antibody interaction, but not necessarily all amino acids that contribute to binding. 
For two antibodies from pannings against TcdB1-1852, ViF088_H10 and ViF090_A6, an almost 
identical MER in the N-terminal part of the GTD was identified, it comprised aa 24- 84 or 
aa 23-83, respectively. These amino acids make up three alpha helices that belong to an alpha 
helical bundle at the toxins N-terminus (Figure 3-14).   
Figure 3-13: Screening ELISA after TcdB-fragment panning for SH1429_C10 
93 clones were screened for production of TcdB-fragment phage specifically binding to SH1429_C10 (red) but 
not an unrelated isotype control antibody (black). Green bars: anti pIII antibody was coated as capture antibody 
to confirm production of a randomly chosen clone. Blue bars: anti pIII was coated and instead of produced 
monoclonal TcdB-fragment phage, Hyperphage was added afterwards as a control of the detection system. 
Columns 1-4 of the ELISA plate were incubated with TcdB-fragment phage originating from the first panning 
well, 5-8 from the second and 9-12 from the third well. 
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For ViF087_B10, TcdB-fragment phage screening resulted in identification of only one hit 
(aa 289-313). Nevertheless, together with the data of the peptide array an epitope region could 
be assigned (Figure 3-14).   
 
The MER of the two best neutralizing mAbs generated in this study (ViF087_A10 and 
SH1429_B1) was also located in the GTD (aa 423-433). For ViF087_A10 the signal noise 
ratio of epitope presenting clones in screening ELISA was comparably low, nevertheless the 
MER was in accordance to the peptides bound in the peptide array for both mAbs.  
Figure 3-15: Epitope region of ViF087_A10 
Combined data of Peptide array and phage display; the epitope region of ViF087_A10 is highlighted in green 
on the 3D model of TcdB GTD generated by X-Ray crystallography (PDB 2bvm); the two helices involved in 
substrate recognition are shown in blue. 
Figure 3-14: Epitope regions of ViF090_A6, ViF088_H10 and ViF087_B10 
Combined data of peptide array and phage display: Epitope of ViF090_A6 and ViF088_H10 (left); epitope of 
ViF087_B10 (right) highlighted in green on the 3D model of TcdB GTD generated by X-Ray crystallography 
(PDB 2bvm) 
ViF090_A6 and ViF088_H10 ViF087_B10 
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As shown in Figure 3-15 for ViF087_A10, the MER is located directly next to the Rho-
GTPase binding groove of TcdB. 
For ViF087_E1 a MER between aa 528 and aa 543 was identified, which corresponds to the 
C-terminus of the GTD (Figure 3-16) and overlaps with the peptide that was strongly bound 
in the peptide array (aa 522-537). 
 
For ViF137_A9 and ViF137_E7 the MERs identified by phage display were in accordance 
with the results of the peptide array (Figure 3-17). Albeit, for both antibodies three cluster of 
peptides were identified by peptide array, for ViF137_A9 only one, and for ViF137_E7 two 
of the three clusters were confirmed by phage display. 
 
The MER of ViF137_C3 was located in the N-terminal portion of the CROPs and spanned 
aa 1860-1992 (Figure 3-18). For SH1429_D6, the MER found spans a stretch of 118 amino 
acids in the middle of the CROPs (aa 2010- 2118) and the MER of SH1429_G6 aa 2228-2291. 
The seven remaining mAbs ViF137_A3, ViF137_A6, ViF137_E4, SH1429_B10, 
SH1429_C10, SH1429_G1 and SH1429_H7 all bound to the C-terminal part of TcdB, the 
MERs of these epitopes resembled the last 70-130 aa of the CROPs domain.  
180° 
  
Figure 3-17: Epitopes 1 and 2 of ViF137_A9 and ViF137_E7  
Epitopes (combined data of peptide array and phage display) are highlighted in red on the crystal structure of 
the CROPs (PDB 4np4) 
Figure 3-16: Epitope of ViF087_E1 
The epitope of ViF087_E1, an α-helical structure at the C-terminus of the GTD is shown in green on the 
crystal structure of this domain (PDB 2bvm) 




For ViF137_A3, ViF137_A6, ViF137_C3, SH1429_C10, SH1429_D6 and SH1429_G1 a 
reevaluation of the results of the peptide array was done after identification of the MERs by 
phage display. In all cases peptide clusters were identified that were strongly bound by the 
respective antibodies and which were in accordance to the MERs identified by phage display 
(Table 3-5 and Supplementary Table 7-1 - Supplementary Table 7-5). 
Taken together, the data generated by peptide array and phage display are in good agreement 
(Table 3-5) and give valuable information about the antibody-antigen interactions. 
 
 
A summary of the epitopes of the antibodies generated in this study, also in comparison with 
already published epitopes of neutralizing antibodies is given in Figure 3-19. Hence some 
epitopes overlap with already published epitopes, also a lot of novel epitopes were identified. 
 
 
Figure 3-18: Epitope of ViF137_C3 
Epitope of ViF137_C3 shown in red and residues protected from H/D exchange by Bezlotoxumab in grey 
(Orth et al. 2014) 
180° 
  
Figure 3-19: Positions of the epitopes on TcdB 
Epitopes of the antibodies generated in this study (upper pane, the two best neutralizers are shown in red) 
and epitopes of neutralizing antibodies generated by others (lower panel). The numbers correspond to the 
numbers of the mAbs used in the tables. 
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Table 3-5: Summary of antibody characterization 
# mAb name 
Antigen 
(Panning) 




(position of 1st aa of 15mer 
peptide) 
Minimal epitope 
region (MER, Phage 
display) 
No of clones 
included in 
MER  
1 ViF087_A10 TcdB1-1852 TcdBFL, (≤50%), TcdB1-1852 - aa 402-404 and aa 412-422 aa 423– 433 
5 (low signal : 
noise ratio) 
2 ViF087_B1 TcdB1-1852 TcdBFL, (≤50%), TcdB1-1852  +/-  no hits  - 
3 ViF087_B10 TcdB1-1852 TcdBFL, (≤50%), TcdB1-1852  +/- aa 288-294 (not exclusively)  aa 289-313 1  
4 ViF087_E1 TcdB1-1852 TcdBFL, TcdB1-1852, TcdBGTD +/- aa 522 aa 528- 543 16 
5 ViF087_E7 TcdB1-1852 TcdBFL, TcdB1-1852, +/-  no hits  - 
6 ViF087_F1 TcdB1-1852 TcdBFL, (≤50%), TcdB1-1852,  -  no hits  - 
7 ViF087_F3 TcdB1-1852 TcdBFL, TcdB1-1852, +/-  no hits  - 
8 ViF087_G10 TcdB1-1852 TcdBFL, TcdB1-1852, -  no hits  - 
9 ViF087_G11 TcdB1-1852 TcdBFL, TcdB1-1852, -  no hits  - 
10 ViF087_H5 TcdB1-1852 TcdBFL, TcdB1-1852, +/-  no hits  - 
11 ViF088_C5 TcdB1-1852 TcdBFL, TcdB1-1852, TcdBGTD +/-  no hits  - 
12 ViF088_E10 TcdB1-1852 TcdBFL, TcdB1-1852, -  no hits  - 
13 ViF088_H10 TcdB1-1852 TcdBFL, TcdB1-1852, TcdBGTD +  aa 24- 84 12 
14 ViF090_A6 TcdB1-1852 TcdBFL, TcdB1-1852, TcdBGTD +  aa 23- 83 4 
15 ViF090_G5 TcdB1-1852 TcdBFL, TcdB1-1852, -  no hits  - 
16 ViF091_B10 TcdB1-1852 TcdBFL, (≤50%), TcdB1-1852 -  no hits  - 
17 ViF137_A3 TcdBCROPs TcdBFL, TcdBCROPs  + aa 2342-2344 (not exclusively) aa 2284- 2364 6 
18 ViF137_A6 TcdBCROPs TcdBFL, TcdBCROPs + aa 2340- 2344 aa 2275- 2364 23 
19 ViF137_A9 TcdBCROPs TcdBFL (≤50%), TcdBCROPs + 
KYYF° (°=D or N)  
aa 1854-1862, 2080-2086 and 
2212-2216 
aa 1858- 1868 13 
20 ViF137_C1 TcdBCROPs TcdBFL (≤50%), TcdBCROPs +  no hits  - 
21 ViF137_C2 TcdBCROPs TcdBFL (-), TcdBCROPs +  no hits  - 
22 ViF137_C3 TcdBCROPs TcdBCROPs (-) + aa 1922-1938 aa 1860– 1992  3 
23 ViF137_E4 TcdBCROPs TcdBFL, TcdBCROPs + aa 2342-2344 aa 2292- 2364 18 
24 ViF137_E7 TcdBCROPs TcdBFL, TcdBCROPs + 
*KYYF° (*=I, S or D; ° =D or N) 
aa 1852-1860, 2078-2084 and 
2212-2216 
2 epitopes, shared motif: 
DKYYFNP  AA 1862-
1868 and 2220- 2226 
17+5 
 
25 SH1429_B1  TcdBFL TcdBFL, TcdB1-1852 +/- aa 414-424  aa 423- 432 8 
26 SH1429_B10  TcdBFL TcdBFL, TcdBCROPs -  aa 2267-2364 19 
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# mAb name 
Antigen 
(Panning) 




(position of 1st aa of 15mer 
peptide) 
Minimal epitope 
region (MER, Phage 
display) 
No of clones 
included in 
MER  
27 SH1429_C10  TcdBFL TcdBFL, TcdBCROPs + aa 2340-2342 aa 2333-2363 15 
28 SH1429_D6  TcdBFL TcdBFL, TcdBCROPs + aa 2078 and 2084  aa 2010– 2118 6 
29 SH1429_G1  TcdBFL TcdBFL, TcdBCROPs + aa 2316-2324  aa 2267– 2364 10 
30 SH1429_G6  TcdBFL TcdBFL, TcdBCROPs (-) +  aa 2228 - 2291 4 
31 SH1429_H7  TcdBFL TcdBFL, TcdBCROPs +  aa 2276– 2364 11 
 
 




Clostridioides difficile is the causative agent of Clostridioides difficile associated diarrhea 
(CDAD) (Bartlett et al., 1978). During the last decades the incidence of CDAD in Germany 
has risen to 5-20 cases per 100.000 per year (Burckhardt et al., 2008; Lübbert et al., 2014). 
Due to its association with antibiotic treatment and the resulting high potential for develop-
ment of antibiotic resistance, the US Centers for Disease Control and Prevention (CDC) 
classify CDiff as an urgent threat (Centers of Disease Control and Prevention, 2013). To fight 
this threat new therapeutic strategies are urgently needed. 
The main virulence factors of CDiff are the two large clostridial toxins TcdA and TcdB that 
are secreted upon CDiff outgrowth (Just et al., 1995a, 1995b). In 2016 the anti-TcdB antibody 
Bezlotoxumab was approved for prevention of CDI recurrence by the FDA. The co-developed 
anti TcdA antibody Actoxumab did not show clinical efficacy and failed in clinical phase 3 
(Merck Newsroom Home, 2015). Bezlotoxumab reduced the CDI recurrence from 26% to 
16% in the clinical phase 3 study (MODIFY II) (Wilcox et al., 2017). Because of this limited 
efficacy, the increasing number of CDiff toxinotypes and the fact, that currently three different 
TcdB receptors and a potential carbohydrate structure are described, new studies to describe 
neutralizing and non-neutralizing epitopes are necessary, for further rational development of 
antibody combinations that potentially improve clinical outcome and/ or vaccine design 
(Greco et al., 2006; Gupta et al., 2017; LaFrance et al., 2015; Rupnik and Janezic, 2016; Tao 
et al., 2016; Yuan et al., 2015). 
For this reason, antibodies were generated against TcdB, which were characterized in respect 
of antigen binding, domain specificity and TcdB neutralization in an in vitro assay. 
Furthermore, two different approaches were used for epitope mapping to identify vulnerable 
epitopes on TcdB. 
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4.1 Antibody phage display led to generation of a diverse antibody repertoire 
To generate novel human monoclonal antibodies targeting TcdB, a phage display approach 
was chosen. Phage display had already been successfully used previously to isolate 
neutralizing single-domain antibodies against TcdA from an llama immune V(H)H library 
(Hussack et al., 2011). However, aim of this study was to generate fully human antibodies, 
which are better developable for possible future clinical use, since antibodies derived from 
other species require chimerization or humanization to reduce immunogenicity but still have 
lower percentual human content compared to fully human antibodies (Almagro et al., 2018). 
Thus, the large naïve human scFv libraries HAL9 and HAL10 were used in a pooled approach 
for antibody generation (Kügler et al., 2015). To generate more diverse antibodies that bind to 
different regions of TcdB, six antibody selections were performed on either TcdBFL TcdB1-
1852 or TcdBCROPs. The panning strategies differed in regards of the TcdB fragments used, the 
negative selection strategy and/or the temperature. All six panning strategies led to the 
identification of unique and specific antibodies, therefore enrichment of specific antibody 
phage directed against the different TcdB variants was successful either way. Nevertheless, 
the two pannings at 37 °C against TcdB1-1852 resulted in a very low number of unique scFvs 
(1+2), therefore the panning against the CROPs and TcdBFL was only performed at ambient 
temperature. 
Sequencing with subsequent CDR analysis revealed the isolation of a total of 36 unique 
antibodies. The usage of HAL9 and HAL10 library in a pooled approach led to an enhanced 
but not exclusive selection of lambda antibodies (80%). This result is in accordance to previous 
studies (Kügler et al., 2015) and also in humans the majority of the antibodies are λ-antibodies 
(ratio λ: κ = 2:1) (Murphy and Weaver, 2018). Furthermore, antibodies of four different IGH 
V genes were isolated with the majority of IGHV1 and IGHV3 and lower numbers of IGHV5 
and IGHV6. IGHV2, IGHV4 or IGHV7 antibodies were not selected. Presence of IGHV2 and 
IGHV7 is very rare in HAL9 and HAL10 libraries as well as in humans and IGHV4 antibodies 
are often lost during the panning procedure with a ten- fold decrease in frequency from 18,3% 
to 1,8%. Taken together the V gene distribution of antibodies generated in this study resembles 
the distribution already described for antibody selections using HAL9 and HAL10 and by 
large also the distribution in humans (Kügler et al., 2015). 
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4.2 Validation of antibody- antigen binding after format change  
For further validation and characterization, the antibody candidates were converted into the 
bivalent scFv-Fc format. Due to a fast cloning and better production rates, this format is 
preferred over the full IgG format for the rapid screening of a higher number of candidate 
antibodies (Bujak et al., 2014). Furthermore, due to the dimerization facilitated by the Fc part 
and the presence of the Fc part itself it has IgG-like properties which makes it well suitable 
for preclinical characterization (Frenzel et al., 2016).  
After subcloning and successful production in mammalian cell culture, thirty-one antibodies 
were tested for antigen binding and domain specificity in an antigen ELISA on four different 
TcdB variants (TcdBFL, TcdB1-1852, TcdBCROPs and TcdBGTD). By antigen ELISA on the 
respective panning antigen, it was validated that the antibody- antigen interaction was not 
impaired by the format change from scFv to scFv-Fc and switch of the production system, 
since all antibodies bound to their respective antigen, albeit 2 out of 31 only weakly. Never-
theless, these two antibodies were not excluded from further assays and neutralization tests. It 
had been shown in another study aiming at generation of diphtheria toxin neutralizing 
antibodies, that there is no (good) correlation between binding to immobilized antigen on an 
ELISA plate and neutralization efficacy (Esther Wenzel, unpublished data). 
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4.3 Folding or epitope shielding influences binding to TcdBFL 
Even though all antibodies bound to their respective panning TcdB variant, almost no binding 
to TcdBFL was detected for five antibodies and for further seven antibodies the binding to 
TcdBFL was drastically reduced compared to the respective panning antigen. 
All these antibodies have in common that they were generated on fragments of TcdB, instead 
of TcdBFL. Since equal amounts (100 ng) of all variants have been used for coating of the 
microtiter plates and TcdBFL has a higher molecular weight compared to its fragments, one 
easy explanation would be that there were less molecules of TcdBFL available for antibody 
binding, thus resulting in a lower signal. However, most antibodies did not show a decreased 
binding therefore this theory is less likely. Also coating of the same molarity of each TcdB 
variant is difficult to realize, since coating efficacy may vary from protein to protein depending 
on ionic groups and hydrophobic regions. A second possible reason is that the epitopes or 
binding regions of some antibodies might not be accessible in the tertiary structure of the 
full-length TcdB. For TcdA, a homologues toxin, a 3D model of the holotoxin is available that 
was generated on the basis of electron micrographs by Pruitt and coworkers. This model nicely 
reveals the complex domain organization of the toxin. One feature that might help 
understanding the different binding of TcdB fragments and TcdB FL is that the C-terminal 
CROPs form a long tail that lays back onto the N-terminal portion of the toxin (Pruitt et al., 
2010). And even though the CROPs domain of TcdB is considerably smaller, electron 
micrographs of TcdB suggest a similar domain organization (Pruitt et al., 2010). Epitope 
regions that are located at the interface between CROPs and the N-terminal portion of the toxin 
might be less accessible in the full-length toxin due to steric hindrance, which would explain 
reduced antibody binding on full-length TcdB. Different antibody binding on TcdB fragments 
and full-length TcdB with antibodies derived from this study was also shown by Chung et al 
(paper submitted). To circumvent the generation of antibodies which do not bind the 
full-length toxin, antibody generation strategies with alternating panning rounds on full-length 
TcdB and TcdB fragments could be applied. Alternating panning strategies have already 
successfully been used to generate antibodies against complex target structures like membrane 
proteins (Jones et al., 2016). 
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4.4 Panning against TcdBFL preferentially led to isolation of antibodies 
binding the CROPs 
The next question to address was the domain specificity of the generated antibodies. By 
performing six pannings with different TcdB variants and different panning strategies a broad 
variety of different antibodies with different antigen binding profiles should be generated. 
In an antigen ELISA seventeen of the 31 antibodies bind to TcdB1-1852. These antibodies mainly 
originate from the four pannings against TcdB1-1852; only one derives from the panning on 
full-length TcdB. Just four of these mAbs also bind to TcdBGTD which indicates that 
preclearance of the library by incubation on immobilized TcdB1-1128 prior to the panning in 
cases of panning ViF087 and ViF090 was successful, but not complete. If a stricter selection 
strategy is needed, the preclearance step should be combined with soluble competition during 
the panning as already described earlier (Stausbøl-Grøn et al., 1996). Here a broader domain 
specificity was aimed for, therefore soluble competition was omitted. 
Worthy of mention is that in this domain mapping ELISA, an enzymatically inactive GTD 
mutant (D286/288N) was used. Even though the amino acid sequences differ in only two 
amino acids, the overall structure of the domain might be slightly changed. Therefore, epitopes 
might not be accessible or conformational epitopes might be destroyed. Loss of antibody 
binding after mutation of single amino acids had already been described for antibodies 
targeting the diphtheria DT toxin (Bigio et al., 1987). Due to this reason and possible different 
folding of the various TcdB variants epitopes within the GTD must not be excluded for the 
antibodies binding to TcdB1-1852 but not to TcdBGTD in this assay. 
Almost half (14 /31) of the antibodies characterized in this study bind to TcdBCROPs, even 
though this domain has only been present in two out of the six panning strategies (Panning on 
TcdBFL and on TcdBCROPs). Most interestingly, the panning on TcdBFL almost exclusively 
resulted in the generation of mAbs directed against the CROPs. In in vivo studies it had already 
been shown, that the CROPs elicit strong antibody responses (Yang et al., 2014). One possible 
reason might be the repetitive structure of the CROPs. Due to this feature, structural elements 
present in the CROPs are overrepresented in the panning. Furthermore, as already mentioned 
above, the CROPs could shield epitopes on the other domains, thereby inhibiting generation 
of antibodies against these structures.  
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4.5 A cell-based assay revealed generation of neutralizing antibodies 
To evaluate if antibodies have been generated that might be suitable for further preclinical 
development an in vitro neutralization assay of TcdB was performed.  
Since the CROPs, the GTD and also the TLD of TcdB all harbor epitopes that can be targeted 
for neutralization with antibodies (Anosova et al., 2015; Babcock et al., 2006; Marozsan et al., 
2012; Maynard-Smith et al., 2014; Wang et al., 2012) all 31 mAbs were subsequently tested 
in an in vitro TcdB neutralization assay which is based on cell rounding of Vero cells.  
All 31 mAbs reduced the percentage of round cells after TcdB treatment to some extent and 
therefore had slight neutralizing effects. Best neutralization was achieved using ViF087_A10 
or SH1429_B1, two antibodies that both bind to TcdB1-1852 with almost complete inhibition of 
cell rounding which was also confirmed in a second assay using serial dilutions of these anti-
bodies. Unfortunately, comparison of the in vitro neutralization efficacy of the antibodies 
obtained in this study with antibodies from other studies is not possible, since there is no 
common standard protocol for the in vitro neutralization assays. Therefore the assays differ in 
regards of amounts and productions of TcdB used, incubation/ intoxication times and in cell 
lines used (Anosova et al., 2015; Babcock et al., 2006; Kroh et al., 2018; Marozsan et al., 
2012; Schmidt et al., 2016).  
However, of the 14 antibodies directed against the CROPs domain, only two (ViF137_E7 and 
SH1429_H7) had neutralization efficacies of more than 50%. Maynard-Smith and coworkers 
have previously shown that in contrast to TcdA, generation of neutralizing antibodies against 
the CROPs of TcdB is difficult even in vivo by immunization (Maynard-Smith et al., 2014).  
Deduced from the homologue TcdA, the CROPs of TcdB harbor 4 putative carbohydrate 
binding sites (Greco et al., 2006; Orth et al., 2014). These multiple sites might contribute 
avidity effects upon cell binding. Therefore, neutralization via the CROPs might be difficult. 
Furthermore, these binding sites share structural similarity (repetitive elements) but differ in 
respect to their amino acid sequence, making it difficult to develop a single antibody that 
completely blocks all interactions between the CROPs and the carbohydrate structures.  
Nevertheless, the approval of Bezlotoxumab for therapy of recurrent CDAD explicitly proves 
that neutralization via this C-terminal domain is possible (Babcock et al., 2006; Wilcox et al., 
2017). 
Crystal structure analysis has shown that the already approved therapeutic antibody 
Bezlotoxumab binds to two epitopes within the CROPs, therefore it was suggested that this 
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antibody blocks interaction of the CROPs with carbohydrate structures on the cell surface 
(Orth et al., 2014). Nevertheless, binding of Bezlotoxumab to aa 1878-1961 also inhibits 
interaction with CSPG4 receptor (Gupta et al., 2017) which would be a second possible mode 
of neutralization. Finally, due to the existence of two epitopes within the CROP domain also 
aggregation of the toxin as neutralization mechanism cannot be excluded. Today, it is not clear 
which of the above mentioned is the major neutralization mechanism.  
However, due to the three receptor binding sites that are located at the border, or outside of 
the CROPs (Chen et al., 2018; Gupta et al., 2017; LaFrance et al., 2015; Tao et al., 2016) 
possible neutralization of TcdB by inhibition of CROPs binding to their target carbohydrate 
structures might be hidden due to uninterrupted binding to the other receptors. To test whether 
the anti-CROPs mAbs might lead to an increased neutralization when applied together with 
neutralizing mAbs directed against the N-terminal fraction of TcdB (aa 1-1852) a combinatory 
neutralization assay was performed where each of the anti- CROPs mAbs was tested for in 
vitro neutralization of TcdB in combination with ViF087_A10 and SH1429_B1, respectively.  
Even though there was a slight increase in neutralization when antibodies were applied in 
combinations compared with neutralization mediated by the single antibodies ViF087_A10 
and SH1429_B1 these effects were rather just additive than synergistic. 
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4.6 Discovery of a novel neutralizing epitope within the GTD 
For future development of novel therapeutic antibodies against TcdB as well as for a rational 
vaccine design a deeper understanding of the molecular actions of TcdB is required, especially 
about potentially vulnerable regions or epitopes that can be targeted with antibodies or used 
as a vaccine to evoke a potent neutralizing antibody response. With the broad panel of 
antibodies generated in this study valuable information can be generated by correlating the 
neutralization efficacies of the respective antibodies to their epitopes or epitope regions. With 
the antigen ELISA already a rough domain mapping was performed, but resolution was very 
low with the few antigen fragments used in this assay. To narrow down the binding regions of 
the antibodies an epitope mapping was performed. Until now gold standard for epitope 
mapping is still X-ray crystallography, which provides profound information of antibody 
antigen interaction on nearly atomic resolution (Toride King and Brooks, 2018). This method 
has also been applied to elucidate the epitopes bound by Bezlotoxumab (Orth et al., 2014). 
Nevertheless, this method is very laborious and therefore not applicable for a larger set of 
antibodies. Furthermore TcdB is not easy to crystallize: up to date there are only structures of 
fragments or domains of TcdB solved (Alvin and Lacy, 2017; Orth et al., 2014; Shen et al., 
2011).  
Therefore, as a first approach a peptide array was chosen. This method is feasible for screening 
higher numbers of antibodies in parallel and is comparably uncomplicated. A prerequisite for 
binding of antibodies to peptides immobilized on the array surface is, that the antibodies bind 
to continuous epitopes, not including complex folding (Abbott et al., 2014). Due to the peptide 
length of 15 aa the presence of conformational epitopes is limited to alpha helical epitopes, 
which represent an interim stage between a linear and a conformational-discontinuous epitope. 
To compensate the lack of complex epitopes in the peptide array, a phage display approach 
that also allows the identification of conformational epitopes was used (Cariccio et al., 2016; 
Moreira et al., 2018). Highest resolution, down to single amino acid level, is achieved with 
mutagenesis libraries (Rojas et al., 2014). However, due to its size of 270 kDa this is not 
feasible for full-length TcdB and most likely not even all of its domains. Therefore, a TcdB-
fragment library was used instead.  
In both assays all antibodies were included, since also information about epitopes that don’t 
convey neutralization is important.  
Unfortunately, but not unexpectedly, epitope mapping by peptide array was not successful for 
the majority of the tested antibodies. By testing the antibodies for binding to SDS and 
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ß-Mercaptoethanol treated TcdB variants in an immunoblot, it had been demonstrated that 
most antibodies, binding to the N-terminal portion of TcdB, do not bind to the linearized 
antigen, whereas most antibodies directed against the CROPs do. Generally, antibodies that 
don’t bind to SDS and ß-Mercaptoethanol treated proteins are likely to bind to discontinuous 
or conformational epitopes; but even antibodies that do bind to SDS and ß-Mercaptoethanol 
treated proteins must not necessarily bind to linear epitopes, because there might be a certain 
degree of backfolding of the protein during the assay, as had been indicated by Park and 
coworkers (Park et al., 2007).  
Nevertheless, even though ViF087_A10 does not bind to denatured TcdB in immunoblot and 
SH1429_B1 only very weakly, binding to 15 mer peptides on the peptide array was detected. 
Core of their epitope is a continuous amino acid stretch within the GTD (aa 423-433 and 423- 
432, respectively). This epitope, primarily found by peptide array, was also confirmed by 
antigen fragment phage display. Remarkably, both neutralizing antibodies bind to the same 
epitope region: a surface exposed α- helix that is located in direct proximity to the residues 
involved in substrate recognition (aa 436-456) (Swett et al., 2012) (Figure 5b). Additionally, 
ViF087_A10 also reacted with two peptides in the peptide array that correspond to a 
neighboring α- helix located N-terminal of the alpha helix found by both methods. Folding of 
the alpha helix and the orientation of the two neighboring helices towards each other is 
probably mostly destroyed by SDS and ß-Mercaptoethanol treatment, which would explain 
the abolished binding in immunoblot. 
Due to the localization of this neutralizing epitopes at least two neutralization mechanisms are 
possible for ViF087_A10 and SH1429_B1: i) inhibition of substrate binding or ii) sterical 
hindrance of TcdBGTD translocation through the pore. The latter mode of action has recently 
been described for the humanized monoclonal antibody PA41 that binds to aa 290-360 (Kroh 
et al., 2018).  
For ViF090_A6 and ViF088_H10 both epitope mapping was only successful with the phage 
display approach, these antibodies bound to a bundle of alpha helices at the very N-terminus 
of TcdB which is conserved among large clostridial toxins and is described to guide the GTD 
towards the cell membrane after release into the cytosol (Geissler et al., 2010) 
For one antibody, ViF137_C3, an epitope (aa 1860-1992) was found, that includes one of the 
epitopes described for Bezlotoxumab [aa 1902-1907 are partially protection from H/D 
exchange by bezlotoxumab (Orth et al., 2014)]. Nevertheless, TcdB neutralization achieved 
with this antibody in cell rounding assays was only less than 50%. Unfortunately, in vitro 
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neutralization efficacies of these two antibodies are not comparable, due to variations in the 
assay (Babcock et al., 2006). Moreover, the resolution of epitope mapping by phage display 
was not high enough for this antibody to determine whether these antibodies interact with the 
same amino acids of TcdB or not.  
For most antibodies that exclusively bind to TcdB1-1852 and TcdBFL in antigen ELISA it was 
not possible to determine the epitope by neither of the methods tested. As shown by 
immunoblot assay, these mAbs most likely bind to complex discontinuous epitopes, including 
amino acids that are located far apart on the primary structure of TcdB and only come into 
close proximity upon folding of the polypeptide chain. Such epitopes cannot be identified 
using peptide arrays and might also be hard to display on phage.  
The latter is due to several possible reasons. Firstly, there is a selection pressure towards 
smaller antigen fragments during library cloning and packaging (Faix et al., 2004). When 
amino acids contributing to the epitope are too far apart on the primary structure, the 
corresponding TcdB-fragment phage will be underrepresented during the panning. Secondly, 
the TcdB fragments corresponding to the epitopes could be toxic for E. coli, which would lead 
to a loss of clones producing these fragments during library packaging; indeed, the quality 
control of the library, which included sequencing of 92 clones, could not prove complete 
coverage of the TcdB sequence, (which could of cause also be due to the number of clones 
sequenced which was ~0,001% of the library). Thirdly, especially TcdB fragments that have 
higher hydrophobicity might missfold or aggregate and finally, some peptides might not be 
efficiently secreted via the sec pathway. To overcome this possible limitation, Kügler et al. 
already suggested the use of a combination of phage vectors using the sec pathway, the twin-
arginin translocation system (Paschke and Höhne, 2005) and the signal recognition particle 
pathway (Valent, 2001) for translocation into the periplasm (Kügler et al., 2008).  
For 18 of the 31 antibodies minimal epitope regions were identified. For 13 antibodies, 
including the two most potent neutralizing antibodies generated in this study, results of TcdB-
fragment phage display and peptide array were consistent and mutually supportive, providing 
profound information about neutralizing and non- neutralizing epitopes of TcdB. These new 
findings might be of great value for future development of therapeutic antibodies targeting 
TcdB and TcdB fragment or - epitope based vaccines.  
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4.7 Conclusion and outlook 
In this study, phage display technology was used to generate a broad panel of fully human 
monoclonal antibodies that target TcdB, one of the main virulence factors of Clostridioides 
difficile and target of new therapeutic approaches.  
ELISA and Immunoblot analysis proved TcdB binding and domain specificity of 31 analyzed 
antibodies and confirmed the selection of antibodies with diverse binding characteristics. 
Using a cell-based in vitro assay, it was shown that especially two antibodies efficiently 
neutralize TcdB induced cell rounding. These two antibodies might be candidates for further 
preclinical development. Also, future therapeutic use of these antibodies, preferably as 
antibody combination with antibodies targeting different domains or epitopes, is easily 
conceivable due to the human origin of these antibodies. 
By correlating the epitopes identified via TcdB-fragment phage display and peptide array with 
in vitro neutralization efficacy, a new epitope within the glucosyltransferase domain of TcdB, 
which conveys neutralization was identified. Summing up the results of this study as well as 
of anti TcdB-antibody studies published by others the following regions may be addressed in 
future development of neutralizing antibodies or TcdB based vaccines:  
i) aa 290-360 (Kroh et al., 2018),  
ii) aa 423- 432 (epitope of the two best neutralizers generated in this study),  
iii) aa 1372- 1493, involved in binding to poliovirus receptor- like protein-3 (LaFrance 
et al., 2015; Manse and Baldwin, 2015),  
iv) aa 1810-1850, involved in CSPG4 binding (Gupta et al., 2017) 
v) aa 1430-1600 containing the FZD- cysteine rich domain binding region (Chen et 
al., 2018); 
whereas the following regions should be omitted:  
i) the N- and C-terminus of the GTD, since antibodies against these regions generated 
in this study did not show significant neutralization,  
ii) the C-terminus of the CROPs [antibodies generated in this study as well as by 
others were poor neutralizers (Gupta et al., 2017; Maynard-Smith et al., 2014)] 
Taken together, this study delivers valuable information for further development of new 
therapeutics against TcdB, as well as for a more rational, epitope based, vaccine design. 
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7 Supplemental information 
 
 
Supplementary Figure 7-1: Size exclusion chromatography 
100 µg scFv-Fc were loaded onto a Superdex 200 10_300 GL column. Retention of the protein in the column 
was detected via UV absorption. Plotted are milli-absorbance-units against retention volume. For ViF087_F3 > 
50% of the protein were in higher molecular state or aggregates. For SH1429_B1 most protein detected was 
bivalent scFv-Fc 




Supplementary Figure 7-2: TcdB coverage  
TcdB coverage was assesd by sequencing of 92 clones. 60 among them had correct TcdB-pIII fusions and were aligned to the TcdB-
Protein sequence 




Extract from the result of epitope mapping by peptide array. For antibodies where specific binding to peptides was detected, the 15 strongest signals 
are given with signal intensity, position of first amino acid of the peptide and peptide sequence.  
 
Supplementary Table 7-1: Results of peptide array a) 
ViF087_B10 ViF087_A10 SH1429_B1 
Peptide Pos Signal* Peptide Pos Signal* Peptide Pos Signal* 
YETNNTYPEVIVLDA 1708 2111 LNPAISEDNDFNTTT 414 5131 LNPAISEDNDFNTTT 414 2675 
SFTAVVGWKDLEDGS 2072 1166 PAISEDNDFNTTTNT 416 3929 PAISEDNDFNTTTNT 416 1919 
DMLPGIQPDLFESIE 288 1116 ISEDNDFNTTTNTFI 418 2555 ISEDNDFNTTTNTFI 418 1587 
ISKVYMDDSKPSFGY 1494 816 QIENRYKILNNSLNP 402 2448 KSKNLPELSTLLQEI 790 1199 
LPGIQPDLFESIEKP 290 618 LNFNNKIYYFDDSFT 2060 1752 EDNDFNTTTNTFIDS 420 1085 
KDKTLANKLSFNFSD 1772 599 EDNDFNTTTNTFIDS 420 1615 NDFNTTTNTFIDSIM 422 938 
AHHNEDLGNEEGEEI 2040 490 ENRYKILNNSLNPAI 404 1050 DDLVISEIDFNNNSI 1148 290 
ATGSVIIDGEEYYFD 2342 450 NDFNTTTNTFIDSIM 422 785 YKRNYFEGSLGEDDN 534 235 
GWLDLDEKRYYFTDE 2324 353 DDLVISEIDFNNNSI 1148 661 FNTTTNTFIDSIMAE 424 222 
RYKILNNSLNPAISE 406 347 NSLNPAISEDNDFNT 412 245 DPDTAQLVISEGSGS 2356 169 
IIYDKQKNFINYYKA 178 341 KTPYDSVLFQKNIED 600 180 TYKKSGRNKALKKFK 62 71 
IDTYKKSGRNKALKK 60 334 YSGLVRVGEDVYYFG 2188 71 HTVTDDIDHFFSAPS 1178 65 
TGKLIIDENIYYFDD 1926 324 LSESDVWIIDVDNVV 1338 70 SYYEDGLIGYDLGLV 1802 62 
QPDLFESIEKPSSVT 294 320 VQLQGDKISYEAACN 582 65 HLDESGVAEILKFMN 1556 60 
GIQPDLFESIEKPSS 292 315 GEDDNLDFSQNIVVD 544 65 NTSDSLMSFLESMNI 1576 60 
*= Aggregate red foreground median 
hits probably corresponding to the epitope;  
sticky peptides, reacting with majority of antibodies 
less than 10% signal intensity compared to highest signal 
  







Supplementary Table 7-2: Results of peptide array b) 
ViF087_E1 ViF137_A9 ViF137_E7 
Peptide Pos Signal* Peptide Pos Signal* Peptide Pos Signal* 
FDDARAKAQFEEYKR 522 10135 FVTVGDDKYYFNPIN 1856 7216 FVTVGDDKYYFNPIN 1856 54987 
ETSDPLLRQEIEAKI 1050 8572 LEDGSKYYFDEDTAE 2082 6052 DMENESDKYYFNPET 2214 28010 
GKDEFNTDIFAGFDV 654 8038 SLVETEGVFTLLDDK 1128 4090 KDLEDGSKYYFDEDT 2080 26800 
ELVERWNLAAASDIL 258 4950 LGKYLRVGFFPDVKT 450 2821 LEDGSKYYFDEDTAE 2082 26780 
VKDSYCSNLIVKQIE 390 4596 KDLEDGSKYYFDEDT 2080 2749 IYDMENESDKYYFNP 2212 15888 
FLINTLKKTVVESAI 136 2379 DMENESDKYYFNPET 2214 2608 DGSKYYFDEDTAEAY 2084 15106 
ISLSLTLQDEKTIKL 1538 1946 IYDMENESDKYYFNP 2212 2351 TGFVTVGDDKYYFNP 1854 12431 
LLDRIRDNYEGEFYW 1250 1670 TGFVTVGDDKYYFNP 1854 2323 NLIDDIKYYFDEKGI 2236 10518 
EKISSLARSSERGYI 564 1373 MELGKYLRVGFFPDV 448 2291 GWKDLEDGSKYYFDE 2078 10109 
MANVRFRTQEDEYVA 12 1300 GINLIDDIKYYFDEK 2234 2190 GINLIDDIKYYFDEK 2234 8409 
GVQNIDDNYFYIDDN 2140 1266 DGSKYYFDEDTAEAY 2084 2042 ENESDKYYFNPETKK 2216 8114 
ESGVQNIDDNYFYID 2138 1251 TVGDDKYYFNPINGG 1858 1995 LITGFVTVGDDKYYF 1852 6644 
DRIRDNYEGEFYWRY 1252 1172 ENESDKYYFNPETKK 2216 1922 GDDKYYFNPINGGAA 1860 6096 
EGINAIIEVDLLSKS 1410 1120 SKYYFDEDTAEAYIG 2086 1733 CKGINLIDDIKYYFD 2232 5844 
QFGYINIEDKMFYFG 2272 1098 DKYYFNPINGGAASI 1862 1178 TVGDDKYYFNPINGG 1858 5342 
*= Aggregate red foreground median 
hits probably corresponding to the epitope (s);  
sticky peptides, reacting with majority of antibodies 
less than 10% signal intensity compared to highest signal 
  







Supplementary Table 7-3: Results of peptide array c) 
ViF137_A3 ViF136_A6 ViF137_E4 
Peptide Pos Signal* Peptide Pos Signal* Peptide Pos Signal* 
DSHFISFEDISETDE 880 3433 GSVIIDGEEYYFDPD 2344 4975 ATGSVIIDGEEYYFD 2342 10020 
GWLDLDEKRYYFTDE 2324 3269 ATGSVIIDGEEYYFD 2342 3292 TGKLIIDENIYYFDD 1926 6770 
GSVIIDGEEYYFDPD 2344 3247 QEDEYVAILDALEEY 20 2170 GSVIIDGEEYYFDPD 2344 5340 
GWIYDMENESDKYYF 2210 3196 PEYTSEHFDMLDEEV 328 1833 GWLDLDEKRYYFTDE 2324 4345 
GYINIEDKMFYFGED 2274 3004 NEYSKEIDELNTYIE 212 1447 ESGVQNIDDNYFYID 2138 4298 
QEDEYVAILDALEEY 20 2969 QQNELEDSHFISFED 874 1434 LDLDEKRYYFTDEYI 2326 4075 
QQNELEDSHFISFED 874 2818 DFTGKLIIDENIYYF 1924 1409 KLIIDENIYYFDDNY 1928 3414 
EGESINYTGWLDLDE 2316 2629 YSKEIDELNTYIEES 214 1350 SFTPSYYEDGLIGYD 1798 3055 
PEYTSEHFDMLDEEV 328 2618 ILSFTPSYYEDGLIG 1796 1243 QEDEYVAILDALEEY 20 2909 
TGKLIIDENIYYFDD 1926 2514 WSFDDARAKAQFEEY 520 1228 YTGWLDLDEKRYYFT 2322 2795 
LEDGSKYYFDEDTAE 2082 2451 DMLPGIQPDLFESIE 288 1155 YFGETYTIETGWIYD 2200 2664 
YIPEYTSEHFDMLDE 326 2449 NELEDSHFISFEDIS 876 1135 GYINIEDKMFYFGED 2274 2650 
GWKDLEDGSKYYFDE 2078 2142 HFISFEDISETDEGF 882 1128 DFTGKLIIDENIYYF 1924 2641 
ATGSVIIDGEEYYFD 2342 2081 IAATGSVIIDGEEYY 2340 1094 ILSFTPSYYEDGLIG 1796 2603 
VGEDVYYFGETYTIE 2194 1921 GINLIDDIKYYFDEK 2234 1052 TYREPHLSIYDVLEV 1194 2574 
*= Aggregate red foreground median 
hits probably corresponding to the epitope;  
sticky peptides, reacting with majority of antibodies 
 
  







Supplementary Table 7-4: Results of peptide array d) 
SH1429_C10 SH1429_D6 SH1429_G1 
Peptide Pos Signal* Peptide Pos Signal* Peptide Pos Signal* 
VYYFGETYTIETGWI 2198 697 ATGSVIIDGEEYYFD 2342 468 ESGVQNIDDNYFYID 2138 48218 
IAATGSVIIDGEEYY 2340 621 FKYFAHQNTLDENFE 2302 374 EGESINYTGWLDLDE 2316 30247 
YSGLVRVGEDVYYFG 2188 611 KLIIDENIYYFDDNY 1928 322 GVQNIDDNYFYIDDN 2140 22512 
EYIAATGSVIIDGEE 2338 563 LLDRIRDNYEGEFYW 1250 305 GWLDLDEKRYYFTDE 2324 15276 
ESDKYYFNPETKKAC 2218 530 TGKLIIDENIYYFDD 1926 301 PEYTSEHFDMLDEEV 328 12238 
QAVEYSGLVRVGEDV 2184 524 NIYYFDDNYRGAVEW 1934 290 YIPEYTSEHFDMLDE 326 11412 
DTAQLVISEGSGSGS 2358 517 GSVIIDGEEYYFDPD 2344 286 INIELSESDVWIIDV 1334 11018 
PETKKACKGINLIDD 2226 483 YFGETYTIETGWIYD 2200 269 VELVSTALDETIDLL 1008 10522 
GVQNIDDNYFYIDDN 2140 463 GWKDLEDGSKYYFDE 2078 240 GSVIIDGEEYYFDPD 2344 10021 
QNIDDNYFYIDDNGI 2142 382 GWIYDMENESDKYYF 2210 229 HFDMLDEEVQSSFES 334 9448 
ATGSVIIDGEEYYFD 2342 362 VEYSGLVRVGEDVYY 2186 224 ATGSVIIDGEEYYFD 2342 9392 
YFSDSGIIESGVQNI 2130 310 VYYFGETYTIETGWI 2198 223 ESINYTGWLDLDEKR 2318 9350 
TKKACKGINLIDDIK 2228 293 FDDNYRGAVEWKELD 1938 215 TGKLIIDENIYYFDD 1926 9078 
EDVYYFGETYTIETG 2196 288 VIIDGEEYYFDPDTA 2346 206 FDDNYRGAVEWKELD 1938 7804 
VEYSGLVRVGEDVYY 2186 281 DGSKYYFDEDTAEAY 2084 192 NFEGESINYTGWLDL 2314 7679 
*= Aggregate red foreground median 
hits probably corresponding to the epitope;  
sticky peptides, reacting with majority of antibodies 
 
  







Supplementary Table 7-5: Results of peptide array e) 
SH1429_C10 
Peptide Pos Signal* 
LLDRIRDNYEGEFYW 1250 791 
GSVIIDGEEYYFDPD 2344 547 
QEDEYVAILDALEEY 20 513 
NIYYFDDNYRGAVEW 1934 508 
KLIIDENIYYFDDNY† 1928 498 
INYTGWLDLDEKRYY 2320 491 
TGKLIIDENIYYFDD† 1926 450 
DRIRDNYEGEFYWRY 1252 408 
ATGSVIIDGEEYYFD 2342 403 
FESIEKPSSVTVDFW 298 392 
LESFRENLNDPRFDY 154 389 
NFEGESINYTGWLDL 2314 381 
IAATGSVIIDGEEYY 2340 378 
GWKDLEDGSKYYFDE 2078 336 
LDLDEKRYYFTDEYI 2326 334 
*= Aggregate red foreground median 
hits probably corresponding to the epitope;  
† = peptides reacting with majority of antibodies 
Hits from this region were enriched among the highest 
signals, therefore also specific binding is possible in this 
case 
